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2 Scope and objectives 
Conventional methods for the functional characterization of GPCR ligands in cellular assays 
monitor individual signaling pathways such as alterations in calcium-, cAMP or IP3 levels. By 
contrast, although being less specific, label-free assays are integrative approaches, harbouring 
the potential to detect complex signaling networks as the sum of intracellular processes upon 
GPCR activation.  
The aim of this doctoral thesis was to optimize and to explore the potential of two label-free 
methods, namely DMR and ECIS, to functionally characterize ligands of prototypical aminergic 
and peptidergic G-protein coupled receptors. For this purpose, histamine H1 and neuropeptide 
Y (NPY) Y2 and Y4 receptors were selected as examples, as appropriate pairs of selective 
agonists and antagonist as well as corresponding data from various label-dependent assays 
have been available.  
With regard to optimization, various cell types expressing the human H1 receptor (H1R), 
comprising constitutively H1R expressing tumor cells as well as different genetically 
engineered HEK293T cells co-expressing the H1R and the firefly luciferase, were chosen. 
Moreover, to study the effect of adhesion in the label-free assays, the co-expression of human 
macrophage scavenger receptor 1 (hMSR1) was aimed at. As a model system for peptidergic 
GPCR, CHO-Gqi5-mtAEQ cells co-expressing the human NPY Y2 (Y2R) or Y4 receptor (Y4R), the 
chimeric Gα protein Gqi5 and mitochondrially tagged aequorin were selected. 
To study the contribution of individual signaling pathways to the holistic readouts, the 
selective G-protein inhibitors FR900359 (also known as UBO-QIC) and pertussis toxin (PTX) 
were considered appropriate tools.  
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1 General introduction 
1.1 G-protein coupled receptors 
G-protein coupled receptors (GPCR) represent the largest and most versatile group of 
membrane receptors [1-3]. More than 800 GPCRs are encoded in the human genome [4]. The 
GPCRs are grouped in five major phylogenetic classes [5]. The largest branch with about 700 
members comprises the rhodopsin-like receptors [5]. The other groups are the adhesion, 
secretin, glutamate and frizzled/taste receptors [5]. Furthermore, there are more than 100 
(orphan) GPCRs with no identified endogenous ligand or function [6-8]. The G-protein coupled 
receptors are sharing structural similarities comprising an N-terminal extracellular domain, 
seven transmembrane domains,  connected by three extracellular and three intracellular 
loops, and a C-terminal intracellular domain [9]. A broad range of chemical and physical 
stimuli, for exmaple neurotransmitters, ions or light, can activate specific GPCRs, which 
subsequently transduce the signal into cellular responses [10]. Consequently, GPCRs are 
involved in many physiological functions and in a plethora of diseases [11,12]. The majority of 
GPCRs are signaling via heterotrimeric guanosin-5’-triphosphate binding proteins (G-proteins) 
[3], whereas other signaling mechanisms are G-protein independent, involving ß-arrestins or 
GPCR heteromerization [13,14]. Therefore, GPCRs are more precisely referred to as seven 
transmembrane receptors (7TMRs) [15]. More than 30 % of all approved drugs are addressing 
GPCRs [2,10,16], although only about 30 GPCRs are currently targeted [17]. Therefore, there 
is still a large number of GPCRs to be validated for drug discovery.  
1.2 G-protein mediated GPCR signaling  
The heterotrimeric G-proteins were discovered more than 40 years ago [18]. The GPCR 
mediated signal transduction is triggered by agonist binding which induces conformational 
changes of the receptor resulting in the activation of heterotrimeric G-proteins [19]. The G-
proteins consist of three polypeptides, the 39-52 kDa GDP/GTP-binding Gα suďuŶit aŶd the 
Gßɶ diŵeƌ [20]. Befoƌe aĐtiǀatioŶ, the Gßɶ is ŶoŶ-ĐoǀaleŶtlǇ ďouŶd to the Gα suďuŶit. G-
protein activation is resulting in the exchange of guanidine diphosphate (inactive G-protein) 
for guanidine triphosphate (active G-pƌoteiŶͿ iŶ the Gα suďuŶit. Afteƌ GDP-GTP-exchange, the 
G-protein dissociates from the receptor and falls apart into the α- and the ßɶ-subunit. Both 
subunits are then free to stimulate distinct pathways [21]. The duration of signaling depends 
on the rate of the intrinsic GTP hydrolysis by the Gα-subunit and the following re-association 
1.2 G-protein mediated GPCR signaling 
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of Gα-GDP ǁith Gßɶ [22-24]. Up to Ŷoǁ, ϭϲ ŵaŵŵaliaŶ Gα suďuŶits aƌe desĐƌiďed and based 
on sequence of the α-subunit and their functional properties, G-proteins are classically divided 
iŶto fouƌ Đlasses: Gαi/o, Gαs, Gαq/11 aŶd Gα12/13 [22,25,26]. Moreover, 5 Gß- aŶd ϭϮ Gɶ suďuŶits 
are known [25]. WheŶ Đoupled to Gαs oƌ Gαi/o proteins, GPCRs either activate or inhibit 
adenylyl cyclase (AC) activity, followed by an increase or decrease in intracellular cyclic AMP 
(cAMP) levels [27-30]. The second messenger cAMP can, for example, activate cAMP-
dependent protein kinase A (PKA), the Rap guanine exchange factor Epac (exchange protein 
activated by cAMP) or the transcription factor CREB (cAMP response element binding protein) 
[26,31-33]. Gαi/o proteins are also involved in AC-independent responses, e. g. the blockade 
of calcium channels, in the stimulation of G-protein inwardly rectifying potassium channels 
(GIRK) and in the stimulation of phosphodiesterases [3,31]. Fuƌtheƌŵoƌe, Ŷot oŶlǇ Gαi/o- and 
Gαs-pƌoteiŶs ĐaŶ iŶflueŶĐe ACs, ďut also Gßɶ suďuŶits via calcium-calmodulin [25]. Interaction 
ǁith Gαq/11 triggers the stimulation of phospholipase C (PLC) which results in the formation of 
inositol trisphosphate (IP3) and diacylglycerol (DAG). For the α1-adrenergic receptors coupling 
to both the Gαq aŶd the Gα11 subunit was described [34,35]. The stimulation of IP3-sensitive 
receptors, located in the membrane of the endoplasmatic reticulum, results in a release of 
calcium ions into the cytosol. Diacylglycerol can activate the protein kinase C (PKC) [26,31,36]. 
G12 was the last identified Gα pƌoteiŶ subfamily aŶd ĐoŶsists of tǁo ŵeŵďeƌs, Gα12 and the 
Gα13 protein [37]. About 25 different GPCRs have been associated to the activation of the G12 
subfamily [38]. GPCRs ĐoupliŶg to Gα12/13 are activating small GTPases like RhoA [21]. 
Moƌeoǀeƌ, Gα12/13 have received attention in the context of cell proliferation and 
morphological changes [39]. The Gßɶ suďuŶits interact with effectors like mitogen-activated 
protein kinases (MAPKs), phosphatidylinositol-3-kinase (PI3K) and small GTP-binding proteins 
[40]. DissoĐiated Gßɶ suďuŶits aƌe also involved in GPCR desensitization and downregulation 
[41]. Receptor desensitization after agonist activation terminates the signaling process and 
constitutes a significant step in the regulation of GPCR mediated effects [42]. Traditionally, 
GPCRs are characterized by their preferential coupling to distinct G-proteins. However, an 
increasing number of GPCRs has been identified as promiscuous receptors capable of coupling 
to various G-proteins [43,44]. It is worth to mention, that the signaling depends on the cellular 
background [45,46].  
1 General introduction 
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1.3 G-protein independent GPCR signaling 
G-protein coupled receptors do not only use canonical (G-protein mediated) but also non-
canonical (G-protein independent) signaling pathways, for example via ß-arrestins [47-50], to 
transduce ligand binding into a cellular response. Historically, arrestins were discovered 
because of their ability to terminate G-protein mediated signaling by interacting with 
phosphorylated ligand-activated GPCRs [51] and subsequent receptor internalization [52,53]. 
This process involves G-protein coupled receptor kinases (GRKs). After internalization, the 
GPCRs are either degraded or recycled by re-integration into the membrane [54]. Arrestins 
are able to regulate the signaling of the vast majority of GPCRs [55]. In addition to their role 
in receptor desensitization and trafficking these proteins are capable to trigger various 
signaling pathways [56], which are different from classical G-protein mediated effectuation 
[51]. The arrestin family consists of four isoforms (arrestin 1-4) sharing a high sequence 
homology. Arrestin 1 and arrestin 4 are exclusively expressed in the visual system, whereas 
arrestin 2 (ß-arrestin 1) and arrestin 3 (ß-arrestin 2) are expressed ubiquitously [57]. 
Depending on their affinity to ß-arrestin 1 or 2, the receptors are divided into Class A or Class 
B receptors. Class A receptors bind with a higher affinity to ß-arrestin 2 [54]. Among the most 
intensively investigated signaling molecules involved in ß-arrestin parthways are mitogen 
active protein kinase (MAPK) and the Src-family tyrosine kinases [56,58-60].   
1.4 Traditional GPCR assays 
A variety of detection techniques have been established to investigate GPCR-ligand 
interactions, receptor activation and receptor triggered signaling pathways. Traditional GPCR 
assays can be grouped into two categories, namely in ligand-binding assays and functional 
assays. Since the early 1970s, GPCR research advanced with the development of radioligand-
binding techniques [61,62] . Basically, three kinds of ligand-binding experiments can be carried 
out [63]. There are kinetic experiments, where the association (kon) and dissociation (koff) 
constants of a compound of interest are determined. Saturation experiments are used, to 
determine the dissociation-constant (Kd) of the radioligand and the quantity of specific binding 
sites for the compound. Finally, competition experiments are used to determine the binding 
constants (Ki) of non-labeled ligands by displacement of a radioligand. Radioligand-binding 
assays do not provide information on the quality of action, i. e., whether the compound is an 
agonist, inverse agonist or an antagonist [4].  
1.4 Traditional GPCR assays 
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Functional assays using laboratory animals and preparations of isolated were dalready 
performed in the nineteenth century, and played a central role in drug research prior to the 
development of reductionistic cellular and molecular approaches. Nowadays GPCR ligands are 
usually studied on the human receptor of interest expressed in various host cells containing 
the required signaling machinery, enabling the detection and quantification of a distinct 
readout to characterize agonists, antagonists or inverse agonists. 
Classical functional assays for GPCRs are measuring Gαs or q/11 or i/o subtype dependent changes 
of intracellular concentrations of second messengers (e.g. Ca2+, cAMP, IP3) or alterations in 
the expression of reporter genes (Fig. 1.1). These assays are often performed as endpoint 
assays requiring cell lysis. Furthermore, GPCR activation resulting in G-protein-independent 
signaling can be determined by measuring the arrestin recruitment, e. g. by luciferase 
complementation assays.  
 
Fig. 1.1: Examples of cellular signaling pathways activated by GPCRs and exploited for quantification 
in traditional functional assays. 
 
Examples of proximal assays measuring GPCR activation are the [35S]GTPγS binding and the 
steady-state [32P]GTPase assay, which are performed with membrane preprations of cells, for 
example Sf9 insect cells, expressing the receptor of interest [64,65].       
Methods for the determination of transient changes in the cytosolic calcium concentration 
([Ca2+]i), e. g. due to calcium release from intracellular stores such as the endoplasmatic 
1 General introduction 
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reticulum (ER), are popular because of the availability of calcium-sensitive fluorescent dyes 
[66,67]. Calcium sensitive fluorescent dyes, such as Fura-2, Fluo-3 or Fluo-4, can be used to 
monitor intracellular Ca2+ in real time to obtain data from agonist, antagonist and allosteric 
modulators, but not inverse agonists [66,68].  Instead of fluorescent calcium indicators the 
calcium-dependent luminescence emitted by the recombinantly expressed jellyfish 
photoprotein aequorin can be exploited to measure changes in intracellular Ca2+ 
concentrations [69,70] . This method requires genetical engineering of the cells and incubation 
with a luciferin substrate [66,71]. The GPCR-mediated calcium signal is predominantly 
depending on Gαq/11 coupling [72]. However, calcium assays can also be performed in case 
that the cells expressing the receptor of interest are either equipped with promiscuous G 
pƌoteiŶs ;Gα15 oƌ Gα16) or genetically modified to re-direct Gαs aŶd Gαi signaling to calcium 
release using chimeric G-proteins [43,73-75]. The latter has been achieved by replacing the 
last five to nine C-terminal amino acids of Gαs  oƌ Gαi with those of Gαq/11 [76-79].   
To quantify GPCR activity in a reporter gene assay the GPCR dependent gene expression 
results in the biosynthesis of a conveniently detectable protein or enzymatic activity of the 
latter (e. g. luciferase) [66,80]. Luciferases can be grouped according to source, cofactor 
dependence, brightness, emission wavelength, etc. [81]. The most frequently used luciferase 
is the firefly luciferase, which was isolated from Photinus pyralis [82]. The enzyme uses d-
luciferin as a substrate, which is adenosylated, oxydized and, upon AMP release, converted to 
a dioxetanone, falls apart into CO2 and oxyluciferin under emission of light at a maximum 
wavelength of about 560 nm [82,83]. In principle, gene reporter assays are broadly applicable 
to GPCRs and allow the detection of weak agonists (due to signal amplification) and allosteric 
modulators [4,80].  
In addition, G-protein dependent effects the quantification of ß-arrestin recruitment is 
required to identify functionally selective GPCR ligands. Misawa et al. [84] developed a split 
click beetle luciferase complementation assay which is ideal for this purpose. Two inactive 
fragments of luciferase are attached to the receptor and arrestin, respectively.  Upon GPCR 
activation and arrestin recruitment, the fragments come into close proximity and reconstitute 
enzymatically active luciferase [85,86], which provides a robust signals at a low background.  
The current knowledge of GPCR pharmacology has been essentially gained from results 
obtained from conventional second messenger based functional assays, making these 
1.5 Label-free assay platforms 
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technologies indispensable. However, neither method is universal and ideal. Only in rare 
cases, such assays can be performed with native cells reflecting the physiological situation. 
Assay-specific manipulation range from the addition of indicators to complex genetic 
alterations of the cells regarding expression of receptors, effector proteins and gene reporters 
[4]. Moreover, such reductionist approaches, focusing on specific signaling pathways, are 
inappropriate to uncover complex signaling networks which contribute to an overall 
physiological cellular response [8], and attempts to identify orphan receptors or their ligands 
will most probably fail. Label-free assay technologies could overcome some of these problems 
by detecting holistic cellular responses. The most commonly used label-free assays rely on 
impedance-based or optical readouts [87-91]. Label-free assays have been successfully 
applied to characterize not only GPCRs but also various other biological targets such as 
kinases, ion channels and immunoreceptors [92-98].   
1.5 Label-free assay platforms  
Label-free assays usually employ a biosensor to record ligand-induced cellular effects in a non-
invasive manner [99,100]. Living cells, expressing the GPCR of interest are allowed to attach 
to the surface of an appropriate support (e. g. electrode or optical waveguide). A confluent 
cell monolayer is ideal to obtain a stable baseline and to improve the reproducibility of the 
readout [101]. Upon addition of a GPCR ligand, on, minute changes in cellular morphology are 
detected by the sensor [102]. In principle, such a sensor converts a plethora of cellular effects 
(e. g., minor alterations in cell shape, cell adhesion, cell proliferation, cell migration, cell death) 
into a quantifiable signal [102-111]. Up to now, the processes reflected in the signal are not 
fully understood, although. It is assumed that minor cytoskeletal re-arrangements or 
alterations of cell-cell interactions play a major role [90]. Therefore, the signal from a label-
free assay is commonly referred to as a “black box” readout [90], and it remains challenging 
to deconvolute the response and to trace the complex signal back to the contributing 
pathways. 
It is characteristic of label-free technologies that, in contrast to traditional assays, knowledge 
of the involved signaling pathways is unnecessary, real time measurements are performed 
without addition of molecular probes and genetic modifications to enable a distinct readout 
[91]. Label-free techniques are in principle applicable to any GPCR including orphans, provided 
that the receptor is expressed in an appropriate cell type [112]. As label-free assays are 
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quantifying effects rather than resolving individual pathways contributing to an overall 
response, these approach increase the chance to identify biologically active compounds which 
would escape traditional label-dependent assays [54].   
Biosensors can be grouped into distinct groups, according to the method of signal 
transduction. Among others, calorimetric, acoustic or magnetic biosensors are described in 
literature [100,113]. Optical biosensors, detecting and quantifying the index of refraction in 
the cell in close proximity to  the optical sensor [114,115], and impedance-based biosensors 
[91,116] , using electrodes as support for the cells, were employed in this doctoral project and 
are, therefore, explained in more detail in the following and illustrated in Chapter 3, Fig. 3.1. 
A schematic representation of the used label-free methods is shown below (Fig. 1.2).   
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Fig. 1.2: Schematic representation of the label-free techniques DMR and ECIS. (A) Surfaces on the 
bottom of well, containing resonant waveguide grating (RWG), reflecting monochromatic light of a 
speĐifiĐ ǁaǀeleŶgth λ ǁheŶ illuŵiŶated ǁith polǇĐhƌoŵatiĐ light. Mass ƌedistƌiďutioŶ ǁithiŶ ϮϬϬ Ŷŵ 
from the surface is recorded. (B) Electric cell-substrate impedance sensing (ECIS) records the 
electrical impedance of a confluently grown cell-layer. The impedance signal depends on the shape 
of the cells on the electrode.    
 
1 General introduction 
9 
 
1.5.1 Dynamic mass redistribution (DMR) 
Ligand-triggered cellular dynamic mass redistribution (DMR) can be recorded by an optical 
sensor such as a resonant waveguide grating (RWG). RWG came up in the 1990s and was 
originally used to investigate binding of compounds to immobilized receptors [117]. Explained 
in a simplified form, the biosensor consists of a substrate layer, a waveguide film wherein an 
optical grating structure is embedded, a medium and a cell layer [87]. When illuminated from 
the microplate bottom side with broadband light centred at 830 nm in a specific angle, the 
light is moving in parallel through the bottom of each well of the microtiter plate [118]. 
Resulting from the interaction of light with the grating, an evanescent electromagnetic field is 
generated, which decays exponentially from the sensor surface [102]. The electromagnetic 
field interacts with cells in the sensor vicinity and depending on the local refractive index, 
changes of the reflected wavelength can be measured. The readout is recorded as the shift in 
resonant wavelength in picometer (pm) as a function of time [103]. The GPCR-induced cellular 
response leads to alterations in the refractive index close to the sensor surface [87,99]. Mass 
redistributions perpendicular to the sensor are detectable: the signal increases, when mass 
movement is directed to the surface of the sensor, whereas mass movement in the opposite 
direction decrease the signal; mass redistribution parallel to the sensor are not detectable 
[102]. The limiting factor of the DMR method is the penetration depth of the evanescent field, 
which lies between 150 – 200 nm. Just DMR events within this penetration depth can be 
recorded. It is worth to mention that the used long-wavelength light is strong enough to 
illuminate the biosensor but not the cell. Thus, the optical RWG method can be considered as 
a non-invasive analysing technique [8,89,91,99,103,119].     
1.5.2 Surface plasmon resonance (SPR) 
Another optical biosensor, transducing ligand-triggered DMR into a quantifiable signal is the 
surface plasmon resonance (SPR) technology. SPR was first described by Otto in the late 1960s 
and was made commercially available for biomolecular investigations in 1990 [120,121]. Like 
RWG, SPR has proven to be applicable for versatile investigations like receptor-drug, enzyme-
substrate or lipid membrane-protein interactions, among others [122-124]. In general, SPR 
spectroscopy can be applied for monitoring changes of the refractive index of cells, cultivated 
on a metal (usually gold) sensor [125]. Surface plasmon resonance takes place, when a 
monochromatic parallel-polarized (p-polarized) light beam hits the layer of gold under 
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conditions of total internal reflection [126]. P-polarized light is defined as light with an electric 
field direction parallel to the plane of incidence on the metal layer. It is worth to mention, that 
s-polarized light (perpendicular to the surface) does not cause plasmon resonance and 
increases just the background intensity of reflected light [127]. Several instrumental 
configurations exist which are used to excite surface plasmons. These configurations are using 
prisms, gratings or optical waveguides [127]. At a specific angle of incidence, electrons of the 
gold surface are excited to move parallel to the surface (plasmons). The plasmons generate 
an electric field which decays exponentially on both sides of the gold film [128]. DMR within a 
distance of about 300 nm from the sensor surface can be recorded [126]. The interaction of 
incident light with electrons of the golden surface layer is resulting in a dip of the recorded 
intensity level of the reflected light. The angle at which the maximal reduction of the reflected 
light intensity occurs is named resonance angle. The resonance angle depends on optical 
characteristics of the system, like the refractive indices of the media at both sides of the gold 
layer. Because the refractive index at the side of the prism is not changing, the refractive index 
in the direct vicinity of the gold surface alters, if dynamic mass redistribution is directed to the 
sensor [127].   
1.5.3 Electric cell-substrate impedance sensing (ECIS)  
The applicability of electric biosensors to detect morphological changes in live cells upon 
biological, chemical or physical stimuli was first described in the early 1980s [104]. ECIS 
exploits confluent monolayers of cells on gold electrodes [106], for example, embedded in 
wells of microtiter plates, to quantify alterations in the impedance. The cell-covered 
electrodes and reference electrodes are electrically connected by cell culture medium on top 
of the cell layer. Subsequently, small sinusoidal alternating current (AC) voltages at varying 
frequencies are applied to these electrodes and impedance alterations are measured [129]. 
The cells behave as insulators because of the capacitive, non-conducting properties of the cell 
membrane [129]. Due to this characteristic, the current is forced to flow around the cellular 
bodies along narrow gaps under and between adjacent cells at lower frequencies (< 10 kHz). 
At higher frequencies (> 30 kHz), the current can couple capacitively through the cell 
membrane [129]. The technique is quantifying changes in complex impedance (Z) as readout, 
calculated by the ratio of the voltage (is measured by ECIS) to current (is applied by ECIS), as 
defined by Ohm’s law (Z = U(t)/I(t)) [130]. In turn, the complex impedance can be dissected 
into three parameters Rb, α and Cm [131,132]. In the ECIS model, cells are represented as disk 
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shaped objects with insulating membranes, filled with conducting electrolyte solution, which 
are levitating above the electrodes. Rb quantifies the impedance contribution generated by 
adjacent cells. The parameter α describes the impedance due to the restricted current flow 
between cells and electrode. The radius of the cells and the cell-electrode distance are the 
main factors contributing to α. Lastly, Cm describes the average capacitance of the cell plasma 
membrane. It is worth to mention, that it is not possible to distinguish between the apical and 
basal membrane [131,132].  
ECIS is a versatile technique to investigate the cell in a frequency-dependent manner, 
reflecting minute morphological changes, and to distinguish between impedance 
contributions from cell-electrode contact, cell-cell contact and membrane properties. It was 
demonstrated ECIS can be applied to various biological targets including, e.g., GPCRs, tyrosine 
kinase and nuclear receptors [130]. 
1.5.4 ECIS-SPR assay combination 
In the last years several approaches were performed, to combine SPR with other analytical 
methods to increase the information depth [133-135]. The combination of the two most 
widespread label-free techniques is therefore a logical step to record cellular response from 
one and the same cell population [133]. Both techniques are based on different physical 
principles (as shown before) generating complementary readout. Whereas the impedimetric 
assay is providing data integrated over the whole cell body, the optical measurement 
technique detects alterations up to 300 nm perpendicular to the sensor surface. The 
combination of the impedimetric and optic label-free techniques may increase the 
information obtained from the same cell population [133].      
1.5.5 Information on G-protein coupling gained from DMR and ECIS 
Although being considered holistic approaches, the shape of the DMR and ECIS traces can be 
roughly associated with ligand-GPCR interactions resulting in distinct G-protein subtype 
activation [136-138]. Typical signatures of Gαq/11, GαS and Gαi/o mediated cellular responses 
monitored by DMR and ECIS are shown in Fig. 1.3  
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Fig. 1.3: Characteristic DMR (first row) and ECIS (second row) traces as signatures of Gαq/11, Gαs and 
Gαi/o coupling of GPCRs. 
 
Nevertheless, it should be emphasized that the overall response monitored by label-free 
methods can depend on the cell-type, the GPCR, specific or promiscuous G-protein coupling, 
the pharmacological properties of the ligand, the extent of activation/inhibition of different 
pathways including G-protein independent signaling, and possibly many other factors. 
Therefore, these aspects have to be considered when investigating a particular GPCR in a 
specific cellular background by label-free techniques. By analogy with classical experimental 
pharmacology, e. g. on isolated organs, detailed investigations with molecular tools such as 
pathway inhibitors and selective ligands (agonists, antagonists) are mandatory to identify the 
contributing signaling mechanisms in holistic label-free cellular assays. 
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Note: Prior to the submission of this thesis, parts of this chapter were published in cooperation 
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3.1 Introduction 
G-protein-coupled receptors (GPCRs) constitute the largest family of membrane-bound 
signaling proteins, which transmit extracellular stimuli across the cell membrane into the 
cytoplasm by activating heterotrimeric G-proteins [1,2]. GPCRs are involved in a plethora of 
diseases, including inflammation, pain, cardiovascular diseases and neurological disorders [3-
6]. They represent the biological targets of more than 30% of all marketed drugs [7]. In 
addition to those GPCRs addressed by approved drugs, the discovery and characterization of 
orphan receptors still holds a great therapeutic potential [8].  
Various functional assays have been designed and successfully applied to determine the 
ligand-dependent, GPCR-mediated activation or inhibition of cellular signaling cascades, e. g. 
by quantification of second messengers such as cyclic AMP, inositol trisphosphate or calcium 
ions [9]. These assays require specific molecular probes (e.g. Fura-2/AM), and the analytical 
readout is most often based on fluorescence or luminescence. By contrast, label-free 
technologies provide a holistic, unbiased and time-resolved approach to monitor the cellular 
response to a compound of interest (agonist/antagonist). These techniques are becoming 
more and more accepted and appreciated in drug discovery [10], in particular, due to their 
applicability to orphan GPCRs, for which the endogenous ligands and the physiological 
signaling pathways are still to be identified.   
The most widely applied devices to perform label-free cell-based assays rely on measuring (i) 
the electrochemical impedance Z of cell-covered planar electrodes (Fig. 1A) [11-13] or (ii) the 
resonance wavelength λ of cell-covered optical waveguides (resonance waveguide = RWG) 
during experimental stimulation of the cells (Fig. 1B) [14-17]. Although the surface plasmon 
resonance (SPR) technique (Fig. 1C) was developed earlier, it has not yet received the same 
attention for the analysis of cell-based assays as RWG- or impedance-based approaches.  
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Fig. 1: Schematic overview of the most widely applied label-free approaches to monitor cell-based 
assays. (A) Electric Cell-Substrate Impedance Sensing (ECIS) reads the electrical impedance of cell-
covered electrodes with non-invasive AC currents and voltages. The impedance signal Z is sensitive to 
coverage of the electrode with cells and the geometric shape of the cells on the electrode. (B) Surfaces 
that hold a resonant waveguide grating (RWG) reflect monochromatic light of wavelength λ when 
exposed to polychromatic incident light. The resonance wavelength of the reflected light is determined 
by the refractive index close to the surface, making the device sensitive to any change in mass 
distribution in the lower part of the cell body. (C) Monochromatic incident light excites surface 
plasmons under resonance (SPR) conditions along a gold-covered surface. The intensity of the reflected 
light – not dissipated into plasmonic energy – is determined by the refractive index close to the surface. 
Thus, SPR provides very similar information as RWG. (D) Setup for simultaneous monitoring of the 
cellular response by ECIS and SPR. The sensor surface holds two elliptical fields for SPR sensing and 
two much smaller working electrodes for ECIS recordings. The relay allows switching between the 
individual electrodes. RWG = resonance wave guide; ECIS = electric cell-substrate impedance sensing; 
SPR = surface plasmon resonance; I0 = intensity of the incident light; IR = intensity of the reflected light; 
Z = impedance; CE = counter electrode; WE = working electrode. 
 
In SPR the intensity of the reflected light is measured. Intensity readings report on the 
generation of surface plasmons along a gold-coated growth surface. Whereas ECIS is sensitive 
to the dielectric properties of the cell bodies on the electrode, RWG and SPR report on the 
integral refractive index within a distance of 100 to 200 nm from the surface. The refractive 
index is affected by the cell bodies and the distribution of mass along the surface. 
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The basic concepts of all these approaches have been described in detail elsewhere [11,13,16]. 
Thus, we only give a short summary to emphasize those similarities and differences that are 
important for the main conclusion of this study. 
The use of electrochemical impedance measurements to monitor cell-based assays was first 
described by Giaever and Keese [15] and is referred to as electric cell-substrate impedance 
sensing or short ECIS. In ECIS the cells are grown on the surface of thin gold-film electrodes 
deposited on the growth surface. When cells attach and spread on the electrode, the 
impedance increases since the dielectric cell bodies behave like insulating particles forcing the 
current to flow below, between or through the cells, depending on the AC frequency used for 
the measurement. Accordingly, the technique is sensitive to electrode coverage and cell 
morphology. When confluent cell layers are studied, cell morphology determines the 
impedance readout entirely. This phenomenon is based on the fact that cell size as well as the 
tightness of cell-cell and cell-substrate contacts determines the geometric and resistive 
properties of the ionic current pathways around the cell bodies. Any change in cell shape 
causes a corresponding change in the geometry of the current pathways and, thus, the 
measured impedance. Since it is well known that GPCR activation may lead to actin 
cytoskeleton remodeling [14], it is straightforward to apply ECIS as monitoring device in cell-
based assays to investigate GPCR pharmacology.  
In RWG devices [17] the surface for cell growth is manufactured with an optical grating. As a 
consequence polychromatic incident light is reflected as monochromatic light while an 
evanescent electric field is generated at the substrate surface. The evanescent electric field 
penetrates approximately 100 - 200 nm into the sample. The integral refractive index within 
this “sensitive sheet” affects the resonance condition and, thus, determines the wavelength 
of the reflected light. Since the plasma membrane of adherent mammalian cells can be as 
close as 25 nm to the surface (strongly dependent on cell type), the resonant wavelength is 
affected by any mass redistribution, provided that it is localized in the lower part of the cell 
body close to the membrane. With respect to this interpretation of refractive index changes 
the approach is often referred to as "DMR" for dynamic mass redistribution.  
In SPR [16] a high quality glass slide is covered with a thin layer of gold. When the interface 
between glass and gold is hit by a monochromatic laser beam under resonance conditions 
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(wavelength, angle of incidence) the evanescent electric field couples into the conduction 
band electrons of the metal and excites surface plasmons (i.e. electron density fluctuations). 
These plasmons generate an evanescent electric field with a similar penetration depth as the 
one provided by the resonance waveguide grating in the range of 100 to 200 nm (dependent 
on wavelength). The refractive index within this sensitive “sheet” affects the resonance 
condition and thereby modulates the intensity of the refracted light. Accordingly, RWG and 
SPR approaches are both sensitive to the integrated refractive index within the evanescent 
field close to the surface. For any changes that occur on the apical side of the cells or more 
distant from the surface, both, RWG and SPR, are blind. It has been suggested that both 
techniques primarily record signals resulting from changes of the cortical cytoskeleton 
adjacent to the basal plasma membrane. 
Whereas RWG and SPR readouts are closely related, impedance measurements are based on 
very different physics and the signal is integrated over the entire cell body. Thus, optical (RWG, 
SPR) and electrochemical approaches (ECIS) provide complementary information. 
Simultaneous application of these techniques might help to unravel the fine structure and 
patterns of time-resolved response profiles. To explore the potential of such a combination of 
approaches, recently, we developed an experimental setup that allows to apply ECIS and SPR 
[18] to one and the same cell population (Fig. 1D). Since the cells are grown on gold-films for 
either of the two approaches, the gold-film is structured by photolithography to provide 
electrodes for ECIS and measurement fields for SPR. Thus, the ECIS-SPR approach provides 
fully synchronized time course data for both readouts. 
With this ensemble of label-free detection techniques, it was our objective to study the impact 
of cell adhesion on the different readouts. We examined two different cell types, human U-
373 MG glioblastoma cells and bovine aortic endothelial cells (BAEC) that endogenously 
express prototypical class A GPCRs, the histamine H1 receptor (H1R) and the β2-adrenergic 
receptor (β2-AR), respectively. These receptors are well known and have been intensely 
studied on the cellular level with various methods. In addition we studied HEK-293 cells that 
were engineered to stably express (i) the human histamine receptor H1R and (ii) the H1R plus 
the human macrophage scavenger receptor 1 (hMSR1) [19]. The latter is known to support 
and enhance cell-matrix adhesion [20].  
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3.2 Materials and methods 
3.2.1 Cells and culture conditions 
The U-373 MG human glioblastoma cells, endogenously expressing the hH1R, were purchased 
from the American Type Culture Collection (ATTC, Rockville, MD, USA). Cells were cultivated 
in Eagle's Minimum Essential Medium containing L-glutamine and 4.5 g/L  
D-glucose (Sigma, Munich, Germany), supplemented with 3.7 g/L NaHCO3 (Merck, Darmstadt, 
Germany), 110 mg/L sodium pyruvate (Serva, Heidelberg, Germany) and 10 % fetal calf serum 
(FCS, Biochrom, Berlin, Germany). Bovine aortic endothelial cells (BAEC), endogenously 
expressing the β2-adrenergic receptor, were kindly provided by Dr. S. Zink and Prof. Dr. P. 
Rösen (Deutsches Diabetes-Zentrum, Düsseldorf, Germany). These endothelial cells were 
originally isolated from aortae of freshly slaughtered calves as described elsewhere [13] and 
propagated by sequential subcultivation. Cells were cultivated in DMEM containing L-
glutamine and 4.5 g/L D-glucose, supplemented with 3.7 g/L NaHCO3, 110 mg/L sodium 
pyruvate and 10 % FCS. Routine cultures of both cell lines were maintained in 25-cm2 culture 
flasks (Sarstedt, Nümbrecht, Germany) in a humidified incubator at 37 °C and 5 % CO2. Cells 
were subcultivated (1:10) twice a week. 
 
3.2.2 Transfections 
Human embryonic kidney (HEK293T) cells were purchased from the German Collection of 
Microorganism and Cell Cultures (DSMZ, Braunschweig, Germany). HEK293T cells stably 
expressing the CRE controlled luciferase were established as previously described [21]. The 
HEK293T-CRE-Luc cells were stably co-transfected with pcDNA3.1(+)-hH1R. Cells were 
detached from a 25 cm² culture flask by trypsinization one day before transfection. Cells were 
centrifuged (10 min, 300 g) and suspended in medium. Two mL of the cell suspension at a 
density of 5∙105 /mL were seeded into a 6-well flat bottom plate (Sarstedt, Nümbrecht, 
Germany). The plasmid was linearized with PvuI (New England Biolabs, Frankfurt am Main, 
Germany) for 2 h at 37 °C prior to transfection. The linearized vector was purified with the PCR 
purification KIT (Qiagen, Leipzig, Germany) according to the manufacturer’s manual. DNA (2 
µg) was diluted with DMEM without FCS, and 6 µL of the transfection reagent FuGene HD 
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(Roche Diagnostics, Mannheim, Germany) were added. The mixture was vortexed and 
incubated for 15 min before addition to the cells. The medium was removed 32 h later and 
the cells were transferred into a 25 cm² culture flask with DMEM 10 % FCS and hygromycin b 
(250 µg/ml) (A.G. Scientific, San Diego, USA). 24 h later the medium was replaced by fresh 
DMEM supplemented with 10% FCS, G418 (600 µg/ml) (Biochrom, Berlin, Germany) and 
hygromycin b (250 µg/mL). Co-transfected cells were cultured in Dulbecco’s Modified Eagle 
Medium (Sigma, Munich, Germany) containing L-glutamine, 4.5 g/L glucose and 3.7 g/L 
NaHCO3. The medium was supplemented with 110 mg/L sodium pyruvate, 10 % (v/v) fetal calf 
serum as well as the selection antibiotics G418 (600 µg/ml) and hygromycin b (250 µg/ml). 
This co-transfected cell line is referred to as HEK293T-CRE-Luc-hH1R cells.  
A second stable transfectant was generated from the HEK293T-CRE-Luc-hH1R cells by co-
transfection with pIRESpuro3/hMSR1 (kindly provided by Dr. S. Krief, bioprojet Biotech, Saint-
Grégoire, France) encoding the human macrophage scavenger receptor 1 (hMSR1) [19] and 
puromycin resistance. For transfection, the cells were seeded in a six-well-plate (Sarstedt, 
Nümbrecht, Germany) so that they reached approximately 60–70 % confluency on the next 
day. The transfection mixture containing 2 µg of pIRESpuro3/hMSR1 DNA was diluted with 
serum free DMEM, and 6 µL of FuGeneHD transfection reagent were added. The selected 
stable transfectant (HEK293T-CRE-Luc-hH1R-hMSR1 cells) was maintained in DMEM 
supplemented with 10 % FCS, 600 µg/mL of G418, 200 µg/mL of hygromycin b and 0.75 µg/mL 
of puromycin (InvivoGen, San Diego, USA) in a humidified atmosphere containing 5 % CO2 at 
37 °C. Expression of the hMSR1 receptor in HEK293T-CRE-Luc-hH1R-hMSR1 cells was 
confirmed by western blot analysis (fig. A1, appendix). 
 
3.2.3 Chemicals and test compounds 
Chemicals of analytical grade were purchased from Merck (Darmstadt, Germany) unless 
otherwise stated. Stock solutions of histamine dihydrochloride (Acros Organics, Geel, Belgium) 
and ;−Ϳ-isoprenaline hydrochloride (Sigma Aldrich, Munich, Germany) were prepared in 
Millipore water (Merck-Millipore, Darmstadt, Germany) and stored at -20 °C. Shortly before 
the experiments, aliquots were thawed and diluted with Leibovitz’ L-15 medium (Thermo 
Scientific, Darmstadt, Germany) without FCS to the final concentration. 
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3.2.4 Impedimetric assay 
Time-resolved impedimetric monitoring of cell-based assays was performed using the  
ECIS-Z device for 96-well electrode arrays of type 96W1E+. Hardware and disposable arrays 
were from Applied BioPhysics (Troy, NY, USA). Each well holds two circular electrodes of 
350 µm diameter, which are electrically arranged in series. Thus, the device monitors 0.2 mm² 
of a confluent cell layer, corresponding to approximately 2.5∙103 cells, assuming circular cells 
with an average diameter of 10 µm. Prior to seeding any of the four cell types, the electrode 
arrays were cleaned and decontaminated by three successive argon plasma exposures of 30 s 
each (Plasma Cleaner PDC-002, Harrick Plasma, New York, USA). Suspensions of the different 
cell types in their individual culture medium were prepared from close-to-confluent cell layers 
by standard trypsinization techniques. For the measurements 300 µL of culture medium 
containing approximately 9∙104 HEK293T cells/well, 4.5∙104 U-373 MG cells/well or 5∙104 
bovine aortic endothelial cells /well, respectively, were seeded into the individual wells of an 
electrode array. The cells were allowed to attach in a CO2 incubator at 37 °C for 24 h. About 1 
h before the assay was performed, the culture medium was aspirated and replaced by 150 µL 
of pre-warmed L-15 medium without FCS. The arrays were connected to the ECIS device inside 
an incubator (Galaxy 48S, New Brunswick, USA) in a humidified atmosphere (without 
additional CO2) at 37 °C for continuous impedance monitoring. Data was recorded at an AC 
frequency of 4 kHz. After recording baseline data, the test compounds dissolved in L-15 
medium were added, and the cellular response was monitored for approximately 40 min. Time 
course data is presented as the shift of impedance magnitude Δ|Z|(t) relative to the last data 
point before test compounds were added into the wells at time zero. Thus, Δ|Z|(t) = |Z|(t) - 
|Z|(0). The time courses for all test compounds were subsequently corrected for the 
corresponding values of untreated controls (buffer only). 
To the best of our knowledge there is only one technique, fluorescence interference contrast 
microscopy (FLIC), recently developed by Braun and Fromherz [22] allowing the determination 
of the distance between the lower cell membrane and the electrode surface.  HEK293T-CRE-
Luc-hH1R cells and HEK293T-CRE-Luc-hH1R-hMSR1 cells were also studied by recording the 
impedance of the cell-covered electrodes along a frequency band from 10 Hz to 100 kHz 
(impedance spectroscopy). Frequency-resolved impedance data was analyzed according to a 
biophysical model that decomposes the overall impedance of a cell-covered electrode into 
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subcellular contributions as described earlier [23,24]. According to this model, which is 
schematically illustrated in Fig. 2, the overall impedance of the cell layer arises from current 
flow along trans- (dashed lines) and paracellular ionic pathways (solid lines).  These pathways 
are further decomposed in (i) the resistance between adjacent cells (cell-cell junctions, '1' in 
Fig. 2) , (ii) the impedance of the plasma membranes ('2' in Fig. 2) and (iii) the resistance in the 
cleft between basal cell membrane and electrode surface Rcleft ('3' in Fig. 2). This cleft 
resistance Rcleft is defined as: Rcleft = rc2⋅ (ρ / d) with the cell radius rc, the specific resistivity in 
the cleft ρ and the distance between lower membrane and electrode surface d. When the cell 
radius and the specific resistivity of the medium in the cleft underneath the cells are constant, 
Rcleft is inversely proportional to the distance between cell and surface. We analyzed the two 
HEK293T transfectants with respect to their individual resistances in the cell-substrate 
junctions. The results are presented as the average resistance in the cleft between the basal 
cell membrane and the electrode Rcleft. 
 
 
 
Fig. 2: Schematic illustrating the physical model that has been used to analyze impedance spectra of 
the two different HEK293T transfectants with respect to the cleft resistance Rcleft (3). Rcleft describes the 
resistance in the cell-substrate junction which is dependent on the distance between basal cell 
membrane and the electrode surface d. Besides Rcleft the model comprises the parameter Rb (1) to 
account for the resistance between cells and the membrane impedance Zm (2). Solid arrows indicate 
paracellular current flow, whereas dashed arrows indicate transcellular current flow. 
 
 
3.2 Materials and methods 
32 
 
3.2.5 Dynamic mass redistribution assay 
Label-free dynamic mass redistribution (‘DMR’) monitoring was carried out on an EnSpire 
(PerkinElmer, Waltham, USA) multimode reader, which is based on the EPIC optical biosensor 
technology using resonance waveguides (RWG). Prior to RWG-based assays, suspensions of 
cells under study were prepared in their individual culture medium from close-to-confluent 
cell layers by standard trypsinization. For the measurements 40 µL of cells suspended in cell 
culture medium were seeded into uncoated 384-well EnSpire cell assay microplates applying 
the individual densities: 2∙104 genetically engineered HEK293T cells/well, 2.5∙103 bovine aortic 
endothelial cells/well and 1.5∙104 U-373 MG cells/well. The microplates were incubated in a 
humidified atmosphere containing 5% CO2 at 37 °C for 24 h, providing cell layers of 
approximately 90 % confluency. Immediately before starting the experiments, the cells were 
washed four times with L-15 medium and were allowed to equilibrate inside the Enspire 
multimode reader at 37 °C for about one hour. After recording baseline data, 10 µL of the test 
substances dissolved in L-15 medium (concentration 4x) were added with a multichannel 
electronic finnpipette (Thermo Fisher Scientific, Waltham, MA, USA) and the cellular response 
was recorded continuously for 40 min. Time course data is presented as the shift of resonance 
wavelength Δλ(t) relative to the last data point before test compounds were added into the 
wells at time zero. Thus, Δλ(t) = λ(t) - λ(0). The time courses for all test compounds were 
subsequently corrected for the corresponding values of untreated controls (buffer only). 
 
3.2.6 Experimental setup for ECIS-SPR assays 
The dual sensor platform was set up by implementing both techniques, ECIS and SPR, on the 
same sensor chip. The ECIS-SPR chips were prepared from high-refractive-index glass slides 
(2.5cm x 2.5cm) covered with a 5 nm chromium bottom and a 45 nm top gold layer. The metal 
layers were subsequently structured by photolithography and wet etching as described 
previously [18], providing the goldfilm pattern as indicated in figure 1D. A PDMS spacer 
(Sylgard 184 silicone elastomer kit, Dow Corning, Michigan, USA) forming a cell culture 
compatible flow cell was glued on top of the sensor using a non-toxic silicone adhesive (Master 
fix Aquarium Silikon, Warenimport und Handels GmbH, Vienna, Austria). The silicone glue was 
allowed to cure for about 24h. The resulting sensor surface (Fig. 1D) featured two individually 
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addressable small circular ECIS working electrodes (diameter ≈ 1mm) and one large counter 
electrode, which was approximately 100fold bigger in surface area. This counter electrode was 
used as SPR measurement spot at the same time.  Electrodes and SPR sensor spots were 
housed in a common fluid volume of about 500 ʅL. The individual readouts from both 
techniques provide the optical and electrical properties of the cells on the sensor chip 
simultaneously. 
SPR measurements were recorded on a Biosuplar400TSPR system (MiviTec GmbH, Sinzing, 
Germany) at 37 °C. The sensor chip was mounted on top of an F61-glass prism of the Biosuplar 
system using appropriate immersion oil (refractive index: 1.61; Cargille, NJ, USA). The flow cell 
was covered with an acrylic glass lid equipped with in- and outlet ports. After mounting of the 
cell-covered sensor chip, a standard angle scan was performed to localize the angle of 
incidence providing the maximal sensitivity of reflectivity. Subsequently, the SPR system was 
run in kinetic measurement mode, during which changes in reflectivity (∆R) were recorded 
over time (t) at this most sensitive angle of incidence. For ECIS measurements of the same cell 
population the impedance of the two individual working electrodes was alternately measured 
against the common counter electrode on the sensor chip using a Solartron SI-1260 Gain-
Phase-Analyzer (Farnborough, UK). A relay allowed switching between the two working 
electrodes. The impedance magnitude at a sampling 16 kHz (BAEC) or 20 kHz (U-373 MG) is 
plotted as shift in impedance Δ|Z| as a function of time relative to the last value before 
compound addition. The different sampling frequencies used in these experiments are a 
consequence of the different electrodes size in ECIS-SPR compared to the commercial 96well 
ECIS electrode arrays and individual dielectric properties of the two cell types studied here. 
Prior to the experiment, suspension of U-373 MG and bovine aortic endothelial cells were 
prepared from close-to-confluent cell layers by standard trypsinization and seeded at a final 
density of 105 U-373 MG cells/cm2 or 9∙104 bovine aortic endothelial cells/cm², respectively. 
This provided a complete coverage of the sensor surface by cell adhesion within 24 hours. 
Before starting the experiments the individual culture medium was replaced by L-15 medium 
and baseline data was recorded for one hour to allow the system to equilibrate before 
addition of pre-warmed solutions of the test compounds dissolved in  
L-15 medium. Time course data |Z|(t) and R(t) is presented as changes in impedance Δ|Z|(t) 
and reflectivity ΔR(t) relative to the last data point before compound addition at time zero. 
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3.2.7 Fura-2 calcium assay 
The assay was performed as described elsewhere [25]. In brief, after trypsinization, the cells 
were centrifuged at 300 g for 10 min. Thereafter, the medium was discarded and the cells 
were counted in a hemocytometer. To three volumes of cell suspension in loading buffer 
(HEPES (Serva, Heidelberg, Germany) 25 mM; NaCl 120 mM, KCl 5 mM, MgCl2 2 mM, CaCl2 1.5 
mM, glucose 10 mM; pH 7.4) one volume of loading dispersion (1 mL loading dispersion: 2 % 
BSA (Serva); 5 µL Pluronic (Sigma); 4 µL Fura-2 (VWR, Ismaning, Germany)) was added. Cell 
density was adjusted to 106/mL. The prepared suspension was incubated in the dark for 30 
min and subsequently centrifuged. Cells were resuspended in loading buffer and allowed to 
stand in the dark for another 30 min. The cells were washed twice with loading buffer and 
adjusted to a final density of 106/mL. The assay was performed in acrylic cuvettes (VWR) using 
an LS50 B spectrofluorimeter (Perkin Elmer). 
 
3.2.8 Data analysis 
Concentration-response curves were constructed from the recorded time courses after  
correction for the time courses of untreated controls, by measuring the area-under-the curve 
(AUC) of individual response profiles [Δ|Z|(t) or Δλ(t)] from 0 – 40 min for each compound 
concentration.  The concentration of half-maximum cell response EC50 was determined by 
fitting a four-parameter sigmoidal transfer function (Eq. (1)) to the recorded data using 
GraphPad Prism 5.01 (GraphPad Software, San Diego, USA). � = ���� +  (���� − ����) �1 + 10log (��50−�)∙��⁄   (1) 
Herein Y denotes the signal response at a given concentration x, Ymax is the maximal response, 
Ymin is the minimal response, EC50 is the concentration of half-maximal response with the Hill 
slope n. 
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3.3 Results and discussion 
3.3.1 Impedance and DMR response of U-373 MG cells upon hH1R 
stimulation 
As the hH1R is Gαq/11-coupled, activation of the receptor by the endogenous agonist histamine 
leads to an increase in cytosolic Ca2+, inositol-1,4,5-trisphopshate (IP3) and diacylglycerol 
(DAG) concentrations. We studied the response of U-373 MG cells, endogenously expressing 
H1 receptors, to histamine using impedimetric (ECIS) and optical (EnSpire) readouts. Both 
assays were performed under similar conditions. Neither the electrode surfaces (ECIS) nor the 
RWG substrates (EnSpire) were coated with extracellular matrix proteins prior to cell seeding. 
After 5 min of baseline recording, histamine was added at increasing concentrations to the 
individual wells, and the cellular response was studied with a time resolution of approximately 
one min for both methods.  
Figure 3A shows the time course of the impedance change ∆|Z| at a sampling frequency of 
4 kHz when U-373 MG cells were exposed to increasing concentrations of histamine in a typical 
experiment. The response is clearly concentration-dependent and shows a characteristic 
pattern with an initial dip of the signal followed by a pronounced rise. Figure 3B shows the 
same dataset after correcting for the time course of the control (L-15 only). At the highest 
agonist concentration applied, the dip of ∆|)| aŵouŶted to approǆiŵatelǇ  
- 200 Ω within the first two minutes, followed by an increase to more than 900 Ω within 20 
min after addition of histamine. This impedimetric response profile Δ|Z|(t) is in agreement 
with those typically recorded for Gαq/11-mediated responses [12] in other labs. When the area-
under-the-curve (AUC) for the pool of baseline-corrected time courses (fig. 3B) was calculated 
between 0 and 40 min and plotted as a function of the logarithm of the histamine 
concentration, we obtained a sigmoidal curve (Fig 3C) with a pEC50 of 6.52 ± 0.08. 
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Fig. 3: Histamine induced response of U-373 MG cells monitored by ECIS (A-C) and RWG/DMR (D-F). 
(A, D) Representative time courses (performed in triplicate) of the change of iŵpedaŶĐe ∆|)| recorded 
at 4 kHz ;AͿ or resoŶaŶĐe ǁaǀeleŶgth ∆ʄ ;DͿ. (B, E) Tiŵe Đourses of ∆|)| aŶd ∆ʄ ǁere ĐorreĐted for the 
signal upon addition of agonist-free L-15 medium by subtraction. (C, F) Concentration-response curves 
were derived from the area-under-the-curve (AUC) of baseline-corrected data integrated from 0 – 40 
min for four independent experiments, each performed in triplicate.  
 
As shown in figures 3D-F, in case of RWG monitoring, the histamine-induced response was 
concentration-dependent, too, but the pattern (Fig. 3D) was different from the impedimetric 
profile (Fig. 3A). The signal increased rapidly to a maximum within 2-3 min after histamine 
addition, followed by a decline and, in case of histamine concentrations >300 nM, a second 
rise of the signal within 15 - 16 min was observed. This phenomenon was highly reproducible. 
A monotonic fast increase of the signal within the first 5 min after stimulation and a slow 
decrease over the residual observation time (20 min) was reported in the literature when 
dynamic mass redistribution (EPIC) had been applied to Gαq/11-coupled GPCRs [26,27]. To the 
best of our knowledge, two relative maxima in the time-resolved response profile have not 
been reported for Gαq/11-stimulation so far [17,26]. For the normalized signals (Fig. 3E) the 
relative maximum after approximately 3 min became only visible at rather high histamine 
concentrations, suggesting that this effect might be, at least in part, unspecific, resulting from 
receptor-independent, interactions of the agonist (e.g. membrane interactions) or from a 
change in intracellular signaling. AUC analysis of the time profiles from 0 to 40 min revealed 
the S-shaped concentration-response relationship shown in Fig. 3F with a pEC50 of 6.12 ± 0.10. 
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The pEC50 values determined with both techniques are in good agreement but significantly 
different from the pEC50 of 4.87 ± 0.14 (N = 10) determined by Ca2+ mobilization assays using 
Fura-2/AM. The significantly smaller pEC50 values returned by label-free methods may reflect 
the contribution of different signaling pathways to the holistic readouts. Interestingly, both 
time profiles show two extrema: two relative maxima in the RWG-based profile compared to 
a minimum and a subsequent maximum for the impedance-based readout. Whereas the 
impedance minimum and the first relative maximum of the RWG-signal appear approximately 
at the same time after addition of histamine, the impedance maximum and the second 
maximum in RWG-data are slightly shifted along the time axis. At this point we can only 
speculate about the reasons for these observations. Both techniques are sensitive to coverage 
of the surface with cells and changes in cell morphology [17]. But, whereas RWG-based 
recordings report on a dynamic mass redistribution within a short distance from the surface, 
impedance readings reflect changes in cell shape integrated over the entire cell body. Thus, 
individual changes at different positions of the cell body contribute to the two time profiles 
with very different individual weights. Moreover, ECIS-readings report on the geometry of 
ionic current pathways which are determined by the position of the cell membranes. In 
contrast, time course data recorded by RWG-based devices mirror a displacement of masses 
which may precede or follow changes in membrane morphology. 
 
3.3.2 Impedance and DMR response of BAECs upon β2-adrenergic 
receptor stimulation  
As β2-adrenergic receptors (β2-AR) are Gαs-coupled, activation results in stimulation of 
adenylyl cyclase and a subsequent increase in the concentration of the second messenger 
cAMP. When BAECs were exposed to increasing concentrations of isoprenaline, there was a 
sustained, monotonic and concentration-dependent increase in ∆|Z| (Fig. 4A). The maximal 
response was achieved within 10 min after agonist addition. After passing the maximum, the 
signal slowly decreased but did not return to basal values within the observation time of 
40 min, as becomes most obvious from the baseline-corrected data in figure 4B. Whereas we 
found this time profile to be highly reproducible for many passages of BAECs, the literature is 
controversial with respect to impedimetric time-resolved response profiles for Gαs-coupled 
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receptors. Similar to our observations, Yu et al. also report on a monotonic impedance 
increase with subsequent decline to basal values within two hours [28]. Other authors 
describe a decrease in impedance below baseline values as a characteristic response to Gαs 
activation [17]. Quantitative analysis of the baseline-corrected time profiles by calculating the 
AUC from time 0 to 40 min gave the concentration-response curve shown in Fig. 4C. The 
corresponding pEC50 was calculated as 6.0 ± 0.4. In previous impedimetric studies we found 
very similar pEC50 values of 6.5 ± 0.2 for the same cell type, using a different electrode size 
[11]. Radioligand binding studies on BAECs revealed a pKD value of 6.97 ± 0.03 for isoprenaline 
[13]. Thus, with respect to potency the different assays – radioligand binding versus functional 
assays - provide a difference up to one order of magnitude for the half-maximum response. 
RWG-based monitoring of BAECs upon isoprenaline stimulation is summarized in Fig. 4D-F. 
The time profiles showed an immediate steep increase to the maxima of the curves after 
addition of the agonist. This maximum is very similar at the highest isoprenaline concentration 
and the medium control. Although the signals appear to be weakly concentration-dependent 
in the baseline-corrected time courses (figure 4E), the AUC data plotted against the 
concentrations of isoprenaline cannot be fitted according by a sigmoidal concentration-
response curve (figure 4F), precluding the calculation of a reliable pEC50 value. Obviously, the 
RWG-based time profiles do not primarily report on the agonist-induced cell response but may 
contain other signal contributions , for instance, perturbations from liquid handling. This 
interpretation is supported by the observation of a similar initial ‘jump’ of the signal in U-373 
MG cells upon addition of histamine (cf. Fig. 3D). Compared to the histamine-induced 
response of U-373 MG cells, the maximum signal change of Δʄ ≈ 7Ϭ pŵ, as oďserǀed here, is 
markedly reduced. 
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Fig. 4: Isoprenaline-induced response of BAE cells monitored by ECIS (A-C) and RWG/DMR (D-F). (A, D) 
RepreseŶtatiǀe tiŵe Đourses ;perforŵed iŶ tripliĐateͿ of the ĐhaŶge of iŵpedaŶĐe ∆|)| reĐorded at 4 
kHz ;AͿ or resoŶaŶĐe ǁaǀeleŶgth ∆ʄ ;DͿ. ;B, EͿ Tiŵe Đourses of ∆|)| aŶd ∆ʄ ǁere ĐorreĐted for the 
signal upon addition of agonist-free L-15 medium by subtraction. (C, F) Concentration-response curves 
were derived from the area-under-the-curve (AUC) of baseline-corrected data integrated from 0 – 40 
min for four independent experiments, each performed in triplicate. 
 
Based on the data shown in figure 4D-F the question arose, why the isoprenaline stimulation 
of β2-AR expressed on BAE cell surfaces is not as properly reported by resonance waveguide 
devices as the histamine response of U-373 MG cells. As the impedance data (Fig. 4A-C) 
provides a concentration-dependent response profile for the very same cell type and assay 
conditions, there is no doubt that the signal transduction machinery is operating. In order to 
exclude that the different supports used in electrochemical and optical analysis are the reason 
for the observed differences, we studied the U-373 MG and the BAEC cells by the combined 
ECIS-SPR technique. By ECIS-SPR analysis, cells from the same population were grown in the 
same medium on a surface covered with a thin gold film for both, the ECIS and the SPR 
readout. 
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3.3.3 Comparing U-373 MG (H1R) and BAE cells (β2-AR) stimulation by 
ECIS-SPR analysis 
Both cell types, U-373 MG and BAEC, were grown to confluency on ECIS-SPR sensor chips as 
shown in Fig. 1D. These supports provided a structured gold-film for performing both, ECIS 
and SPR monitoring on the same sensor surface. As the sensor surface holds only two 
individually addressable ECIS working electrodes and two readout fields for SPR detection, the 
throughput in this experimental setup was limited. Fig. 5A and 5B show typical time course 
data for confluent U-373 MG cells stimulated by 100 µM histamine. Fig. 5A shows the ECIS 
profile and Fig. 5B the SPR profile of the same cell population. The time profiles were very 
similar to those depicted in Fig. 3. The ECIS signal showed a minimum after addition of the 
agonist, followed by a maximum and a slight decrease along the observation period. The SPR-
profile showed two relative maxima, similar to the RWG signals at very high concentrations of 
histamine (cf. Fig. 3D). Thus, in case of stimulation by histamine, the time-resolved ECIS-SPR 
profiles (Fig. 5A, B) were in good agreement with the curves from ECIS and RWG-based 
experiments for U-373 MG cells when recorded separately (Fig. 3).  
When BAECs were studied by ECIS-SPR upon exposure to 10 µM of isoprenaline (Fig. 5C), ECIS 
recordings revealed the same characteristic time course as shown in Fig. 4A. Thus, the cell 
population was responsive to isoprenaline and the impedimetric profile was reproducible. By 
contrast, there was no significant response detectable by simultaneous SPR analysis of the 
very same cell population under identical conditions (Fig. 5D). Thus, both optical methods, the 
RWG and the SPR analysis, failed to determine the agonist potency of isoprenaline on BAECs.  
In contrast to the RWG-based time profiles (cf. Fig. 4E), there are no indications for unspecific 
cell responses due to liquid handling in SPR-based time courses (Fig. 5D).  Please note that the 
cell-covered SPR-chip is not removed from the temperature controlled housing for agonist 
addition. Instead, liquid exchange was performed via inlet/outlet ports so that the cells are 
always covered by liquid, reducing unspecific perturbations. 
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Fig. 5: Representative time-resolved response profiles of U-373 MG cells (A, B) and BAE cells (C, D) 
upon exposure to 100 µM histamine or 10 µM isoprenaline, respectively. (A) and (C) present the 
ĐhaŶge iŶ iŵpedaŶĐe ∆|)| as a fuŶĐtioŶ of tiŵe. (B) and (D) show the time course of the reflectivity 
change ∆R. ECIS and SPR data were recorded for the same cell population on the same sensor chip. 
Due to limited throughput of the ECIS-SPR device, we present typical time courses from single 
registrations. The results were highly reproducible (N = 10 independent experiments, each performed 
in duplicate).  
 
From an earlier study, performing an in-depth analysis of the impedimetric response of BAECs 
upon stimulation with isoprenaline, we learned that BAECs attach rather weakly to their 
growth substrate [11]. At the time we estimated the average distance between basal cell 
membrane and growth support to be larger than 500 nm from optical xz-sections recorded by 
confocal laser scanning microscopy (extracellular space labeled by fluorophore) [11]. 
Therefore, analysis by SPR is illusive, considering that the penetration depth of the evanescent 
electric field (Fig. 6) is in the range of 100 – 200 nm. Thus, the absence of any change in 
reflectivity or resonance wavelength in case of the BAECs is most likely due to an unsuitable 
distance of the cells to the surface. Accordingly, the adhesion of cells to the surface must be 
considered as a factor that potentially affects and modulates the sensor response.  
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Fig. 6: Schematic illustrating the average distance between basal cell membrane and growth support 
d1 or d2 (d1 < d2) with respect to the penetration depth of the evanescent electric field (100 – 200 nm) 
indicated by the gray coded bar. When the distance d becomes larger than the penetration depth of 
the evanescent field, cellular responses are not detectable. 
 
Compounds such as cytochalasin D, which are frequently used to assess the role of the actin 
cytoskeleton in signal transduction [29], are capable of significantly affecting the cell-substrate 
distance and to alter the sensitivity of the optical readout before or during an experiment 
which makes data interpretation rather complex. 
 
3.3.4 Comparison of HEK293T-CRE-Luc-hH1R with and without 
hMSR1 co-transfection 
To explore the dependence of the optical signal on cell adhesion, we performed studies with 
HEK293T-CRE-Luc cells engineered to express either the human histamine H1 receptor alone 
or in combination with the human macrophage scavenger receptor 1 (hMSR1). The latter is 
known to act as a cell adhesion molecule binding to the extracellular matrix (ECM). Scavenger 
receptors were first described by Brown and Goldstein [30]. The macrophage scavenger 
receptor 1 is a trimeric class A membrane glycoprotein with a single cytoplasmic domain, a 
single transmembrane region and a huge extracellular domain which mediates recognition of 
polyanionic ligands, such as modified forms of low density lipoprotein (LDL) [20,31,32]. It has 
been reported that cells expressing the human class A scavenger receptor show improved 
adhesion to the ECM [20]. In agreement to this, HEK cells expressing either hH1R alone 
(HEK293T-CRE-Luc-hH1R) or hH1R and hMSR1 (HEK293T-CRE-Luc-hH1R-hMSR1) behaved very 
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differently during routine trypsinization. Whereas those cells not expressing hMSR1 were 
completely detached from the surface within less than one minute, it took more than ten 
minutes to detach HEK cells co-expressing hMSR1. This observation indicates an improved 
adhesion of the HEK293T-CRE-Luc-hH1R-hMSR1 cells to the growth support as it has been 
reported before [20]. Co-expressing hMSR1 has become an accepted [33] and commercialized 
strategy (‘GripTite™293MSR cells’) to render HEK293T cells more adhesive and thereby 
improve their resistance to detachment in robot-based high throughput drug screening assays 
with automated plate-washing protocols. Both transfectants were studied by ECIS- and RWG-
monitoring with respect to their responsiveness to 1 µM histamine. The results are 
summarized in figure 7. Whereas Fig. 7A presents the ECIS profile of HEK293T–CRE-Luc-hH1R 
to 1 µM histamine, Fig. 7B shows the RWG profile for the same stimulus. ECIS- and RWG-based 
time courses mirror the stimulation of the hH1 receptor, but the cellular response was rather 
weak, in particular, when monitored by RWG. In contrast, under the same conditions, 
HEK293T-CRE-Luc-hH1R-hMSR1 cells revealed signals of higher intensity in both assays, 
especially pronounced and with higher signal-to-noise ratio in the RWG/DMR assay (Fig. 7C, 
D). 
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Fig. 7: (A, B) Representative response traces of HEK293T-CRE-Luc-H1R cells expressing the histamine 
H1 receptor during exposure to 1 µM histamine (red) relative to a medium control (black). The time-
resolǀed iŵpedaŶĐe profile ∆|)|;tͿ is plotted iŶ ;AͿ, the RWG/DMR profile iŶ ;BͿ. (C, D) Response of 
HEK293T-CRE-Luc-H1R-hMSR1 cells co-expressing the histamine H1 and hMSR1 receptor during 
exposure to 1 µM histamine (red) relative to a medium control (black). The time-resolved impedance 
profile ∆|)|;tͿ is plotted iŶ ;CͿ, the RWG/DMR profile iŶ ;DͿ. The iŵpedaŶĐe ǁas reĐorded at a saŵpliŶg 
frequency of 4 kHz. Experiments were performed in triplicate. 
 
This result suggests that expression of hMSR1 improves adhesion and reduces the distance 
between cell and substrate for these cells which strongly increases the height of the signal. It 
is noteworthy that, unlike the RWG-based time courses, the shape of the impedance profile 
(Fig. 7A) was very similar to that of U-373 MG (Fig. 3A) and HEK293T-CRE-Luc-hH1R-hMSR1 
cells (Fig. 7C) upon histamine stimulation. The absence of a second maximum in the time 
course of the resonance wavelength Δλ suggests that the cellular background contributes to 
the observed response profiles apart from the type of GPCR under study and the signaling 
pathways involved.  
In addition to the optical methods, the critical role of cell adhesion becomes obvious from 
analyzing impedance spectra. When the impedance of cell-covered gold-film electrodes is 
recorded along an extended frequency range from 10 Hz to 100 kHz, the resulting impedance 
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spectra are analyzed by a physical model illustrated in Fig. 2, decomposing the integral 
impedance of the cell layer into three major contributors: (i) the resistance between adjacent 
cells Rb as a measure of cell-cell junctions; (ii) the impedance of the cell membranes Zm and 
(iii) the resistance of the electrolyte-filled cleft underneath the cells between the basal cell 
membrane and the electrode surface, Rcleft. According to its definition, Rcleft = rc2⋅ (ρ / d), the 
cleft resistance Rcleft is inversely proportional to the distance d between cell and substrate with 
rc representing the cell radius and ρ aďďreǀiatiŶg the specific electrolyte resistance in the cleft 
between cell and substrate with thickness d. More detailed information on this model is given 
elsewhere [23]. 
Analyzing the impedance spectra of both HEK293T transfectants according to this model 
provides a cleft resistance of Rcleft of (16 ± 4) Ω⋅cm² for the HEK293T-CRE-Luc-hH1R cells devoid 
of the adhesion protein hMSR1. For the co-transfected cells expressing hMSR1, the calculation 
revealed a cleft resistance Rcleft of (31 ± 6) Ω⋅cm². Under the plausible assumption that rc and 
ρ are constant for both cell types (same cellular background, same culture medium), this 
difference in Rcleft translates in a reduction of the distance between cell membrane and surface 
d by approximately 50 %. Although this calculation is based on assumptions, the results further 
support the hypothesis of a shorter distance between the HEK293T-CRE–Luc-hH1R-hMSR1 
cells and the surface, improving RWG-based and to a minor degree impedance-based cellular 
assays. 
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3.4 Conclusion 
The present study has shown that the distance between cell and surface of the sensing devices 
directly affects the sensitivity of both, optical and impedance-based readouts. RWG- and SPR-
based cell monitoring is particularly affected as measurements rely on dynamic mass 
redistribution within a few hundred nanometers away from the surface. In case that the 
distance between cell membrane and the growth surface exceeds the penetration depth of 
the evanescent field, the method becomes insensitive and eventually blind. Therefore, it is 
mandatory to control and, if necessary, to improve cell adhesion to the surface, as 
demonstrated by comparing HEK-293 cells expressing the H1R alone or in combination with 
the adhesion protein hMSR1. The results suggest that impedimetric and optical readouts are 
complementary. The combination of ECIS and SPR may be helpful in this respect as broadband 
impedance analysis allows deconvolution of the individual impedance contributions, providing 
indirect in situ information about the adhesion of the cells upon the sensor surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 The critical impact of cell adhesion in optical and impedance-based label-free assays 
47 
 
3.5 Appendix 
3.5.1 Detection of hMSR1 expression in HEK293T-CRE-Luc-hH1R-
hMSR1 cells by immunoblotting 
Figure A1 shows the result of an immunoblot analysis of cell lysates using an antibody against 
the human macrophage scavenger receptor 1 (hMSR1). As positive control, cell lysates were 
prepared from human epithelial cells derived from pancreas carcinoma PANC-1 which are 
known to express the hMSR1 receptor (lane1). Lane 2 and 3 represent the immunoblot of cell 
lysates prepared from HEK293T-CRE-Luc-hH1R (2) and HEK293T-CRE-Luc-hH1R-hMSR1 cells 
(3). The band at 75 kDa clearly indicates that hMSR1 is strongly expressed by HEK293T-CRE-
Luc-hH1R-hMSR1, but not by HEK293T-CRE-Luc-hH1R cells. This is in accordance with the fact 
that HEK293T-CRE-Luc-hH1R-hMSR1 show improved adhesion to the growth surface 
compared to HEK293T-CRE-Luc-hH1R. 
 
 
Figure A1: Immunodetection of hMSR1. Cell lysates prepared from PANC-1 (positive control, lane 1), 
HEK293T-CRE-Luc-hH1R (lane 2) and HEK293T-CRE-Luc-hH1R-hMSR1 cells (lane 3) were 
immunoblotted after SDS-PAGE using an anti-hMSR1 monoclonal antibody and a secondary detection 
antibody together with a molecular weight marker (right lane). hMSR1 is expressed by HEK293T-CRE-
Luc-hH1R-hMSR1 and PANC-1 cells but not by HEK293T-CRE-Luc-hH1R cells. 
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3.5.2 SDS-PAGE and western blot 
The expression of the human macrophage scavenger receptor (hMSR1) by HEK293T-CRE-Luc-
hH1R-hMSR1 cells was verified by immunoblotting. HEK293T-CRE Luc hH1R hMSR1, HEK293T-
CRE Luc hH1R and PANC-1 cells (ATCC no. CRL-1469), grown in 75-cm² culture flasks (Sarstedt) 
to 80% confluency, were washed twice with ice-cold PBS and harvested by scraping after 
addition of ice-cold RIPA lysis buffer (20 mM TRIS pH=7.8; 200 mM NaCl; 1 mM EDTA; 1 mM 
EGTA; 1% Triton-X-100; 5 mM K2HPO4; 10 mM glycerol phosphate, supplemented with 
protease inhibitor mix (SIGMAFAST Protease Inhibitor cocktail tablets, Sigma)), and the 
samples were vortexed and centrifuged (13000 g, 4 °C, 10 min). The concentration of soluble 
protein was determined according to Bradford (Protein Assay from Bio-Rad Laboratories, 
Munich, Germany). An amount of 10 µg of total protein in sample buffer or 5 µL of a ready-
to-use stained protein marker (Precision Plus Protein Dual Color Standard (BioRad)) were 
loaded per lane onto a SDS gradient gel (Novex 8−16% Tris-Glycine Gel, Fisher Scientific). The 
SDS-PAGE was performed at 140 V for about 1.5 h. The separated proteins were electroblotted 
to a nitrocellulose membrane (pore size 0.2 ʅm, Peqlab Biotechnologie, Erlangen, Germany) 
at 200 mA for 40 min (blotting buffer: Tris (0.3 g), glycine (1.4 g) ad 100 mL of water/MeOH 
(8:2 v/v)). To prevent unspecific binding, the membrane was incubated with Tris-buffered 
saline (20 mM Tris and 150 mM NaCl in water, pH 7.6) containing 1% of Tween-20 (in the 
following referred to as “TBST”) and 5% skimmed milk powder at rt for 2 h. Subsequently, the 
membrane was incubated with the primary antibody (rabbit monoclonal anti-macrophage 
scavenger receptor 1 antibody (ab151707); abcam, Cambridge, UK), diluted 1:2500) with TBST 
+ 2% (w/v) BSA (SERVA, Heidelberg, Germany) under rotation at 4 °C over night. The 
membrane was washed with TBST (4 × 20 min, rt) followed by incubation with the secondary 
antibody (donkey anti-rabbit IgG-HRP (sc-2313, Santa Cruz Biotechnology, Dallas, TX), diluted 
1:10000 with TBST + 2% BSA, under shaking at rt for 1 h. Subsequently the membrane was 
washed with TBST (4 × 20 min, rt), and incubated with the substrate (Clarity Western ECl 
Substrate, BioRad) at rt for 1 min. The bioluminescence was detected with a ChemiDoc MP 
Imaging System (BioRad). 
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Note: Prior to submission of the thesis, parts of this chapter had been submitted for publication 
in cooperation with partners: 
Lieb, S.; Littmann, T.; Plank, N.; Felixberger, J.; Tanaka, M.; Krief, S.; Elz, S.; Bernhardt, G.; 
Wegener, J.; Ozawa, T.; Buschauer, A. 
Label-free versus conventional cellular assays: Functional investigations on the human 
histamine H1 receptor 
The following experiments were performed by co-authors: 
M.T.:  Generated hH1R-split-luciferase and ß-arrestin-split-luciferase constructs for the ß-
arrestin recruitment assay 
J.F.:  Established and performed ß-arrestin recruitment assays  (cf. J.F., PhD thesis, University 
of Regensburg, 2016) 
T.L.:  Performed ß-arrestin recruitment assays with hH1R agonists and antagonists 
N.P.: Established luciferase gene reporter assay and performed gene reporter, aequorin 
calcium and radioligand competition binding assays. 
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4.1 Introduction 
The discovery of the first ‘antihistamines’, later designated as histamine H1 receptor (H1R) [1] 
antagonists, in 1937 and the introduction of first generation antihistaminic drugs for the 
treatment of allergic conditions in the 1940s represent milestones in medicinal chemistry and 
drug research [2,3]. The success story of this well-established class of drugs was continued by 
the development of second generation H1R antagonists with low central effects and reduced 
affinity to off-targets (for a recent review on histamine receptors and ligands cf. [4]). The 
identification and preclinical characterization of the first generation H1R antagonists was 
based on holistic approaches, i. e., pharmacological investigations on isolated organs and 
proof-of-principle studies in experimental animals, e. g., guinea-pigs. Beginning with the 
feasibility of radioligand binding studies more than 30 years ago, there was increasing 
preference for reductionist over holistic approaches in the search for ligands of G protein-
coupled receptors (GPCRs). Nowadays, appropriate techniques of biochemistry and molecular 
biology, e. g., the cloning and expression of receptors, methods for the identification and 
quantification of intracellular signals as well as the resolution of three-dimensional structures 
of the biological targets, enable the study of GPCRs at the cellular and even the molecular 
level. Functional assays are mainly performed on the human orthologue of the respective 
protein expressed in appropriate cells. However, receptor activation may not always result in 
a uniform cellular response [5]. Due to the complexity of signaling networks, the selection of 
an individual pathway, for example, the calcium or the cyclic AMP response, even though 
being considered characteristic of a given receptor, may be insufficient as a readout to 
describe the overall cellular effect. GPCRs can activate or inhibit different effectors in a ligand-
specific manner, known as “functional selectivity” or “biased signaling” [6-12]. Being aware of 
the limitations of the assays relying on specific readouts, holistic cellular approaches should 
provide a more realistic picture of the overall response to a ligand-specific receptor-mediated 
stimulus. Optical and impedimetric methods such as dynamic mass redistribution (DMR; 
resonant waveguide grating, RWG) and electric cell-substrate impedance sensing (ECIS) are 
based on changes of the refractive index close to the surface or the electrochemical 
impedance of cell-covered electrodes, respectively [6,13-21]. As label-free techniques, DMR 
and ECIS are of special value for investigations on orphan receptors, but may also be very 
useful in case of well-known GPCRs such as the H1R [22], for example, with respect to the 
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identification of multiple signaling pathways, i. e., responses beyond those considered in 
conventional assays [6,15-17,19,23-26].  
The canonical signaling of the human H1R implies mainly Gq/11 protein mediated activation of 
phospholipase C, resulting in increased inositol-1,4,5-trisphosphate (IP3) and 1,2-
diacylglycerol (DAG) levels, the mobilization of calcium ions from intracellular stores and 
multiple downstream effects depending on phosphorylation processes [4,27-30].  However, 
the H1R was also reported to be capable of coupling to G-proteins other than Gq/11, i. e., to Gi/o 
[31-33] or Gs [34], and to induce cellular responses such as the activation of nuclear factor κB 
(NFκB) [35] via Gαq/11 and Gβγ. Moreover, the recruitment of β-arrestins and receptor 
internalization upon H1R activation [36,37] as well as H1R/arrestin mediated cellular signalling 
processes, e.g. MAPK activation [38,39] were described.  
Taking into consideration the possible ligand-dependent functional selectivity, the complexity 
of the signaling machinery and the crosstalk within biochemical networks, the characterization 
of ligands in focused functional assays seems incomplete. To compare the the cellular effects 
of H1R ligands depending on the type of readout using genetically engineered HEK293T cells, 
i. e., cells of an identical genetic background, we investigated a set of agonists and antagonists 
(Fig. 1) by DMR and ECIS in comparison to gene reporter (luciferase) assay, calcium assays 
(Fura-2 and aequorin), β-arrestin recruitment and radioligand competition binding. 
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Fig. 1: Structures of compounds investigated at the human histamine H1 receptor. 
 
4.2  Materials and methods 
4.2.1  Histamine receptor ligands  
Histamine dihydrochloride was from Acros Organics (Geel, Belgium), betahistine 
dihydrochloride, diphenhydramine hydrochloride, cyproheptadine hydrochloride, maprotiline 
hydrochloride, fexofenadine hydrochloride and clozapine were from Sigma Aldrich 
(Taufkirchen, Germany), mepyramine maleate was from Tocris Bioscience (Ellisville, MO, 
USA), levocetirizine dihydrochloride and mirtazapine were from Biotrend (Cologne, Germany). 
UR-KUM530 [40], 2-phenylhistamine (PH), 2-(3-bromophenyl)histamine (BrPH) and 2-(3-
trifluoromethylphenyl)histamine (TFMPH) [41,42], histaprodifen [43] and the analogues 
UR-BS280, -BS354, -BS355, -BS358, -BS364 and -BS365 [44] were synthesized as reported 
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previously. The stock solutions of agonists (10 mM) were prepared with Millipore water, 
except for the histaprodifen derivatives (30% DMSO). The stock solutions for antagonists (10 
mM) were prepared in Millipore water, except for clozapine (stock solution in 0.1 M HCl) and 
fexofenadine (50% DMSO). In case that compound solutions were prepared with DMSO, the 
final DMSO concentration was kept below 0.5% in all assays. All stock solutions were stored 
at -20 °C. For label-free measurements, aliquots were thawed and diluted with Leibovitz’ L-15 
medium (Thermo Scientific, Darmstadt, Germany) without FCS. For Fura-2, aequorin Ca2+ and 
luciferase assay, aliquots were diluted with Millipore water.  
 
4.2.2 Genetically engineered cells and culture conditions 
4.2.2.1 HEK293T-CRE-Luc-hH1R and HEK293T-CRE-Luc-hH1R-hMSR1 
cells 
Human embryonic kidney (HEK293T) cells stably expressing the firefly luciferase under the 
control of the cyclic AMP response element (CRE) [45] were stably co-transfected with 
pcDNA3.1(+)-hH1R, encoding the human H1R, and pIRESpuro3/hMSR1, encoding the human 
macrophage scavenger receptor [46], and maintained as published recently (HEK293T-CRE-
Luc-hH1R-hMSR1 cells) [20].   
4.2.2.2 HEK293T-CRE-Luc-hH1R-mtAEQ cells 
To obtain cells expressing mitochondrially tagged aequorin (HEK293T-CRE-Luc-hH1R-mtAEQ 
cells), HEK293T-CRE-Luc-hH1R cells were stably co-transfected with the pcDNA3.1/zeo-mtAEQ 
plasmid. The medium was removed 24 h after transfection, and the cells were transferred in 
a 75-cm2 culture flask with DMEM supplemented with 10 % FCS. Selection was started the 
next day by adding medium containing hygromycin (250 µg/mL), G418 (600 µg/mL) and zeocin 
(40 µg/mL) (Thermo Fisher Scientific, Rockford, IL, USA).  
4.2.2.3 HEK293T-ARRB1-H1R and HEK293T-ARRB2-H1R cells for the 
hH1R-β-arrestin luciferase fragment complementation assay  
The fusion construct of the human H1R (the hH1R cDNA was from cDNA Resource Center, 
Bloomsburg, PA, USA) and the C-terminal luciferase fragment (H1R-ELucC) was generated 
using the previously described construct SSTR2-ELucC [47] by replacing the cDNA of SSTR2 by 
the cDNA of the H1R. HEK293T cells were stably transfected with the pcDNA3.1/myc-HIS (B) 
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vector encoding a β-arrestin isoform (1 or 2) N-terminally fused with the N-terminus of a green 
click-beetle luciferase (ELucN-ARRB1 or ELucN-ARRB2, respectively) [47], and the pcDNA4/V5-
HIS (B) vector encoding H1R-ELucC (Fig. S1, Supporting Information). Cells transfected with 
pcDNA3.1/myc-HIS (B) were cultivated in the presence of 600 µg/mL G418 for up to 3 weeks 
until stable growth was observed. For the cells co-transfected with the pcDNA4/V5-HIS (B) 
vector encoding H1R-ELucC, 40 µg/mL zeocin was used. To determine the H1R-ELucC 
expression, western blot analyses (cf. Fig. S1, Supporting Information) and saturation binding 
studies were performed with both HEK293T-ARRB1-H1R cells and HEK293T-ARRB2-H1R cells 
using [3H]mepyramine (cf. Fig. S2, Supporting Information). 
4.2.3 Radioligand competition binding assay 
HEK293T-CRE-Luc-hH1R cells were grown in a 75-cm2 flask to a confluency of around 80%. The 
cells were detached with 5 mL of trypsin and resuspended in 5 mL Leibovitz’ L-15 medium. 
After centrifugation, the cells were resuspended in L-15 medium. The assays were performed 
in the presence of 5 nM [3H]mepyramine (Hartmann Analytic, Braunschweig, Germany), 
specific activity 20 Ci/mmol, Kd = 4.5 nM, c = 5 nM; nonspecific binding was determined in the 
presence of 10 μM of diphenhydramine hydrochloride (Sigma, Deisenhofen, Germany). 
Samples containing Leibovitz´ L-15 medium, test compound (final concentration in the range 
from 0.1 nM to 10 µM), radioligand, and HEK293T-CRE-Luc-hH1R cells (at a density of 1 million 
cells/mL), were incubated at room temperature and shaken at 250 rpm for 60 min. Filtration 
through glass microfiber filters (Whatman GF/C), pretreated with poly(ethylenimine) (0.3%, 
w/v), using a Brandel 96 sample harvester, separated unbound from cell-associated 
[3H]mepyramine. After three washing steps with buffer (Tris, 75 mM, adjusted to pH 7.4 with 
HCl; MgCl2, 12.5 mM; EDTA, 1 mM), filter pieces were punched and transferred into 96-well 
sample plates 1450-401 (PerkinElmer, Rodgau, Germany). A volume of 200 μL of scintillation 
cocktail (Rotiscint Ecoplus, Roth, Karlsruhe, Germany) was added per well before incubation 
in the dark under shaking at 200 rpm . Radioactivity was measured with a Micro Beta2 1450 
scintillation counter. Ligands were tested in at least three independent experiments each 
performed in triplicate. 
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4.2.4 Aequorin calcium assay 
The assay was essentially performed as described previously for neuropeptide Y (NPY) Y4 
receptor ligands [48]. HEK293T-CRE-Luc-hH1R-mtAEQ cells were detached with trypsin/EDTA 
and DMEM without phenol red and centrifuged at 300 g for 10 min. The cell suspension was 
adjusted to a density of 10 million cells/mL in DMEM without phenol red, and coelenterazin 
(Biotrend) was added, so that the final concentration was 2 µM. The suspension was incubated 
in the dark for 2 h. The cell suspension was diluted 1:20 with loading buffer (HEPES (Serva, 
Heidelberg, Germany), 25 mM; NaCI, 120 mM; KCl, 5 mM; MgCI2, 2 mM; CaCl2, 1.5 mM; 
glucose 10 mM; pH was adjusted to 7.4), and the suspension was incubated in the dark under 
gentle stirring for additional 3 h. In the agonist mode, 18 µL of a 10-fold concentrated solution 
of the test compound in loading buffer were added per well of a white 96-well plate (Greiner, 
Frickenhausen, Germany), and luminescence was measured for 43 s with a GENios Pro 
microplate reader after injecting 162 µL of the cell suspension. Subsequently, 20 µL of a 1 % 
Triton 100-X solution were injected, and light emission was recorded for additional 22 s. In the 
antagonist mode, 2 µL (100-fold concentrated) of the respective antagonist solution were 
incubated with 178 µL of the cell suspension for 15 min. Luminescence was measured after 
injecting 20 µL of agonist solution (10-fold concentrated) for 43 s and, subsequently, after 
addition of 20 µL of a 1 % Triton X-100 for additional 22 s. The fractional luminescence was 
calculated by dividing the area of the first peak (injection of the cell suspension, respectively 
agonist solution) by the sum of the areas of peak 1 and peak 2 (Triton X-100 injection) using 
Sigma Plot 11.0 software. 
 
4.2.5 Fura-2 calcium assay 
The assay was essentially performed as described for NPY Y1 receptor ligands [49]. After 
detachment of the cells with trypsin/EDTA, the cells were suspended in DMEM containing 5% 
FCS and centrifuged at 300 g for 10 min. The medium was discarded, and the cells were 
resuspended in DMEM and counted. To three volumes of the cell suspension, prepared in 
loading buffer (HEPES (Serva), 25 mM; NaCI, 120 mM; KCl, 5 mM; MgCI2, 2 mM; CaCl2,1.5 mM; 
glucose 10 mM; pH was adjusted to 7.4), one volume of loading dispersion (1 mL of loading 
dispersion contained: 2 % BSA (Serva); 5 µL of Pluronic (Sigma); 4 µL of Fura-2 (VWR, Ismaning, 
Germany) was added, so that the final cell density was 1.0 mio cells per mL. The suspension 
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was incubated in the dark for 30 min. Thereafter, the suspension was centrifuged, the cells 
were resuspended in loading buffer and allowed to stand in the dark for another 30 min. The 
cells were washed twice with loading buffer and adjusted to a final density of 1.0 mio cells per 
mL. The assay was performed either in acrylic cuvettes (VWR) using an LS50 B 
spectrofluorimeter (Perkin Elmer) [49] or in transparent 96-well microplates (Greiner) using a 
GENios Pro microplate reader [50]. Assays in the antagonist mode were always performed in 
cuvettes, and the cells were preincubated with the respective antagonist for 15 min.  
 
4.2.6 Luciferase gene reporter assay 
The assay was essentially performed as previously described for the histamine H4 receptor 
[45]. One day prior to the experiments, the HEK293T-CRE-Luc-hH1R cells were adjusted to a 
density of approximately 800,000 per mL in DMEM without phenol red (Sigma Aldrich) 
supplemented with 5 % FCS. 160 µL of the cell suspension were seeded into flat bottom 96-
well plates (Greiner) per well. The cells were allowed to attach overnight. In the antagonist 
mode, the hH1R was stimulated by 300 nM histamine in the presence of the test compound. 
In the agonist mode, the H1R was activated by 20 µL of a 10 fold concentration of the 
respective compound. To obtain a volume of 200 µL per well 20 µL of DMEM were added. All 
wells contained the same amount of DMSO or water. The medium was discarded, and 80 µL 
of lysis buffer (25 mM Tricine (Sigma Aldrich); Glycerol 10 % (v/v) (Merck); EGTA, 2 mM (Sigma 
Aldrich); 1 % (v/v) TritonTM X-100 (Serva); MgSO4 × 7 H2O, 5 mM (Merck); DTT, 1 mM (Sigma), 
the pH was adjusted to 7.8 with HCl) were added to each well. The plates were shaken at 600 
rpm for 15 min. Afterwards, 40 µL of the lysate were transferred into white 96-well plates 
(Greiner). Luminescence was measured with a GENios Pro microplate reader (Tecan, Salzburg, 
Austria). Light emission was induced by injecting 80 µL of the assay buffer (25 mM Gly-Gly, 
(Sigma Aldrich); MgSO4 × 7 H2O, 15 mM; KH2PO4, 15 mM (Merck); EGTA, 4 mM; ATP disodium 
salt, 2 mM (Sigma Aldrich); DTT, 2 mM; D-luciferin potassium salt, 0.2 mg/mL (Synchem, 
Felsberg, Germany); pH was adjusted to 7.8 with HCl). Luminescence [51] was measured for 
10 s. To determine the effect of pertussis toxin (PTX) cells were seeded in medium containing 
0.5 µg/mL PTX. For experiments in the presence of FR900359 (1 µM and 10 µM) or gallein 
(Santa Cruz Biotechnology, Heidelberg, Germany) (20 µM, stock solution: 10 mM in DMSO), 
cells were pre-incubated with the Gαq inhibitor or the Gβγ inhibitor for 2 h.  
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4.2.7 β-Arrestin recruitment assay  
One day before the experiment, HEK293T-ARRB1-H1R and HEK293T-ARRB2-H1R cells were 
trypsinized (0.05% trypsin, 0.02% EDTA in PBS) and centrifuged (400 g, 5 min). The cells were 
resuspended in DMEM without phenol red (Sigma, Steinheim, Germany) supplemented with 
5% FCS, and 90 µL of the cell suspension were seeded in white, TC-treated, flat bottom 96-
well microtiter plates (VWR, Ismaning, Germany) at a density of approximately 100,000 
cells/well. The cells were cultivated at 37 °C overnight in a water-saturated atmosphere 
containing 5% CO2. Shortly before the experiment, the cells were removed from the incubator 
and allowed to equilibrate to room temperature, and 10 µL of agonist solution were added 
per well. The plates were shaken at 25 °C for 60 min. In the antagonist mode, prior to addition 
of the agonist, cells were incubated with the respective antagonist for 15 min. At the end of 
the incubation period, 50 µL of medium were replaced by 50 µL of Bright-Glo luciferase assay 
reagent (Promega, Mannheim, Germany). The plates were vigorously shaken (800 rpm) for 5 
min. Bioluminescence was recorded for 1 s per well using the GENios Pro microplate reader 
(Tecan, Salzburg, Austria). 
 
4.2.8 Impedimetric assay  
For the investigation of H1R agonists on HEK293T-CRE-Luc-hH1R-hMSR1 cells, the assay was 
performed as recently described for histamine [20] using an ECIS-Z device for 96-well 
electrode arrays (type 96W1E+) from Applied BioPhysics (Troy, NY, USA). A volume of 300 µL 
of cell suspension, prepared in DMEM containing 10% FCS from close-to-confluent cell layers 
by standard trypsinization techniques, was dispensed at a density of 9∙104 cells per well. The 
cells were allowed to attach in a CO2 incubator at 37 °C for 24 h. About 1 h before the assay 
the culture medium was replaced by 150 µL of serum-free L-15 medium. Data were recorded 
with the ECIS device inside an incubator (Galaxy 48S, New Brunswick, USA) in a humidified 
atmosphere (without additional CO2) at 37 °C at an AC frequency of 4 kHz for 1 h until the 
baseline was constant (equilibration), and for another 40 min after addition of the agonist at 
various concentrations. For data handling cf. [20].  
For the determination of H1R antagonist activities, after equilibration for 1 h, 150 µL a solution 
of the respective antagonist was added to the cells for an incubation period of about 20 min. 
Subsequently 150 µL of the antagonist containing solution was replaced by the same volume 
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of L-15 medium containing the antagonist at the same concentration and 60 nM of histamine 
to obtain a final agonist concentration of 30 nM, which is known to elicit 80% of the maximal 
response in the absence of an antagonist. 
The effect of pertussis toxin (PTX) was determined in the agonist mode using cells pretreated 
with 1, 10 or 100 ng/mL PTX in DMEM supplemented with 10% FCS for about 20 h. About 1 h 
before the assay the culture medium was replaced by 150 µL of serum-free L-15 medium and 
the assay was performed as described above. To investigate the effect of UBO-QIC, by analogy 
with the antagonist mode, cells were preincubated in the presence of the Gαq inhibitor at final 
concentrations of 0.1, 1 or 10 µM for 20 min. 
 
4.2.9 Dynamic mass redistribution assay 
The assay was performed in the agonist mode as previously described for histamine on 
HEK293T-CRE-Luc-hH1R-hMSR1 cells [20] using an EnSpire (PerkinElmer, Waltham, USA) 
multimode reader. A volume of 40 µL of cell suspension, prepared from close-to-confluent cell 
layers by standard trypsinization, in DMEM containing 10% FCS was dispensed at a densitiy of 
2∙104 cells per well into uncoated 384-well EnSpire microplates. Incubation in a humidified 
atmosphere containing 5% CO2 at 37 °C for 24 h provided cell layers of approximately 90 % 
confluency. The cells were washed four times with serum-free L-15 medium and allowed to 
equilibrate in a volume of 30 µL of the same medium per well in the multimode reader at 37 °C 
for about 1 h. After recording the baseline, the agonist of interest, dissolved in L-15 medium 
(10 µL) was added, the cellular response was recorded for 40 min and data analysis was 
performed as described [20]. 
In the antagonist mode, after equilibration in 30 µL of medium per well for 1 h, a solution of 
the respective antagonist in 10 µL of serum-free L15 medium was added, and the incubation 
was continued for 20 min. Subsequently, another 10 µL of antagonist at the same 
concentration containing additionally 500 nM of histamine to obtain a final agonist 
concentration of 100 nM, which is known to elicit 80% of the maximal response in the absence 
of an antagonist. 
The effect of pertussis toxin (PTX) was determined in the agonist mode using cells pretreated 
with 1, 10 or 100 ng/mL PTX in DMEM supplemented with 10% FCS for about 20 h. The cells 
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were washed four times with serum-free L-15 medium and the assay was performed as 
described above. Experiments in the presence of FR900359 (UBO-QIC) were performed 
according to the antagonist mode with the exception that instead of antagonist the Gαq 
inhibitor was added at final concentrations of 0.1, 1 or 10 µM. 
 
4.2.10 Data analysis 
The data were analyzed with GraphPad Prism 5.01 (GraphPad Software, San Diego, USA) and 
fitted to four-parameter sigmoidal concentration-response curves providing EC50 values of 
agonists and IC50 values of antagonists. For antagonists, pKb values were calculated from IC50 
values according to the Cheng-Prusoff equation [52]. 
 
4.3 Results and discussion 
4.3.1 Functional characterization of H1 receptor agonists 
Changes of the resonance wavelength of cell-covered optical waveguides (resonance 
waveguide = RWG), recorded in DMR, or of the impedance of cell-covered electrodes, 
measured in ECIS, reflect alterations in the cytoskeletal framework [53-55]. As demonstrated 
in a recent study, cell adhesion to the surface is a critical issue in such label-free assays [20]. 
The DMR assay reports on changes in mass distribution inside the cell close to the growth 
surface or outside the cell in the narrow cleft between cell and substrate.  Mass redistribution 
and cell shape changes may be connected in the way that mass redistribution induces cell 
shape changes or vice versa, although difficult to prove or disprove. It is reasonable to assume 
that the signal is dominated by dynamic processes that occur in the actin cortex or by 
remodeling of the actin cortex at the membrane in the vicinity of the growth support [53-55].It 
is noteworthy in this context that the actin cortex is 100 to 1000 nm thick dependent on cell-
type but DMR is only sensitive within 200-300 nm from the substrate surface. The actin cortex 
is not necessarily the exclusive origin for any DMR signal since relocation of other  (even 
extracellular) (macro)molecules that are not linked to the actin cortex or the membrane can 
cause similar DMR signals. This is different from ECIS which is insensitive to mass redistribution 
but reflects changes in the ionic current pathways around or across the dielectric lipid bilayer, 
primarily associated with alterations in cell morphology. Due to the intimate molecular 
4.3 Results and discussion 
62 
 
contact between the plasma membrane lipid bilayer and the adjacent actin cortex, changes in 
the position of the membrane are invariably associated with a concomittant relocation of the 
actin cortex so that both readout techniques often but not always report on similar 
phenomena. Thus, some cellular responses leading to mass redistribution but not to changes 
in the position of the membrane relative to the growth support are visible in DMR but not in 
ECIS and the information gained from both readouts is not identical but complementary .  
Therefore, we performed both, DMR and ECIS, with HEK293T-CRE-Luc cells engineered to co-
express the human histamine H1 receptor and the human macrophage scavenger receptor 1 
(hMSR1) [56], to improve adhesion as described previously [20]. Both label-free assays were 
performed under similar conditions, e. g., with respect to temperature, cell-culture medium 
and equilibration-time. Typical time courses and the resulting concentration-response curves 
are shown in Fig. 2 for histamine as an example. The transient dip of the impedimetric signal 
observed immediately after addition of the agonist is considered characteristic of Gq coupling 
[29] allowing for a discrimination from Gi coupling.   
 
Fig. 2: Histamine induced response of HEK293T-CRE-Luc-hH1R-hMSR1 cells monitored by DMR (A, B) 
and ECIS (C, D). Typical time courses (triplicates) of the change of the resonance wavelength (A) and 
the change in impedance ∆|Z| recorded at 4 kHz (C). Concentration-response curves (B, C) were 
derived from the corresponding area-under-the-curve (AUC) of baseline-corrected data integrated 
from 0 to 40 min. 
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The DMR signal at the highest histamine concentration peaks after an exposure time of 
approximately 10 min, whereas the ECIS signal is retarded and peaks between 15 and 20 min 
after histamine addition. Moreover, the time needed for a maximum response decreases with 
concentration in DMR but increases with concentration in ECIS. This may be interpreted as a 
hint that an agonist-induced mass redistribution precedes cell shape changes, at least at 
higher histamine concentrations. Alternatively, both signals imply different processes 
downstream from receptor activationaccording to individual kinetics.  
The construction of concentration-response curves revealed pEC50 values of 7.49 ± 0.08 and 
7.92 ± 0.16 for histamine in the DMR assay and ECIS, respectively. Comparing the data 
summarized in Table 1 and visualized in Fig. 3, the apparent potencies of histamine differ by 
up to a factor of approximately 10, depending on the type of assay. The highest pEC50 values 
of histamine was determined in the impedance-based (7.92) and the β-arrestin2 recruitment 
assay (7.74), whereas the luciferase gene reporter and the Fura-2 calcium assay yielded the 
lowest potency (pEC50 = 6.87).  
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Table 1.: hH1R agonism determined in different functional assays using genetically engineered HEK293T cellsa,b. For comparison published functional data from 
[32P]GTPase assaysc are included.  
 
gene reporter 
(luciferase) 
β-arrestin1 
recruitment 
β-arrestin2 
recruitment 
Ca2+ 
(Fura-2 AM) 
Ca2+  
(aequorin) 
DMR impedimetry GTPase [40,57,58] 
 
pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax pEC50 Emax 
histamine 6.87 ± 
0.06 
1.00 7.11 ± 
0.1 
1.00 7.74 ± 
0.08 
1.00 6.87 ± 
0.06 
1.00 6.94 ± 
0.15 
1.00 7.49 ± 
0.08 
1.00 7.92 ± 
0.16 
1.00 6.92 [57] 1.00 
UR-KUM530 7.49± 
0.08 
1.05 ± 
0.03 
7.46 ± 
0.03 
0.91 ± 
0.08 
7.97 ± 
0.23 
0.99 ± 
0.06 
6.94 ± 
0.02 
0.99 7.61 ± 
0.06 
1.03 ± 
0.01 
7.99 ± 
0.09 
1.12 ± 
0.03 
8.60 ± 
0.11 
1.15 ± 
0.05 
7.75 [40] 0.94 
betahistine 6.56 ± 
0.25 
0.96  ± 
0.02 
  7.48 ± 
0.04 
0.80 ± 
0.01 
n.d. - 6.69 ± 
0.13 
0.96 ± 
0.02 
6.29 ± 
0.17 
0.71 ± 
0.06 
7.59 ± 
0.08 
0.25 ± 
0.03 
5.85 [58] 0.86 
PH 5.12 ± 
0.15 
0.56 ± 
0.01 
5.25 ± 
0.10 
0.51 ± 
0.03 
6.15 ± 
0.09 
0.67 ± 
0.04 
n.d. - n.d.  6.39 ± 
0.17 
0.50 ± 
0.03 
7.59 ± 
0.33 
0.11 ± 
0.03 
6.14 [40] 0.72 
BrPH 5.46 ± 
0.17 
0.56 ± 
0.05 
5.99 ± 
0.03 
0.43 ± 
0.01 
6.49 ± 
0.01 
0.63 ± 
0.02 
5.90 ± 
0.07 
0.66 n.d.  n.d.  n.d.  6.75 [40] 0.62 
TFMPH 5.81 ± 
0.06 
0.62 ± 
0.02 
5.68 ± 
0.06 
0.38 ± 
0.01 
6.73 ± 
0.10 
0.55 ± 
0.06 
n.d. - n.d.  6.56 ± 
0.15 
0.71 ± 
0.03 
7.16 ± 
0.18 
0.62 ± 
0.12 
6.71 [40] 0.61 
histaprodifen 
  5.85 ± 
0.02 
0.46 ± 
0.01 
6.48 ± 
0.12 
0.47 ± 
0.06 
n.d. - n.d.  n.d.  n.d.  6.95 [57] 0.62 
 
a Experiments were performed using HEK293T cells expressing hH1R and additional constructs: luciferase gene reporter: HEK293T-CRE-Luc-hHϭR Đells; β-
arrestin recruitment assay: HEK293T-ARRB1-H1R and HEK293T-ARRB2-H1R cell; Fura-2 calcium assay: HEK293T hH1R CRE-Luc cells; aequorin calcium assay: 
HEK293T-CRE-Luc-hH1R-mtAEQ cells; DMR and impedimetry (ECIS): HEK293T-CRE-Luc-hH1R-hMSR1 cells.  
 
b Data represent mean values ± SEM from at least three independent experiments performed in triplicate, except for UR-KUM530 and BrPH in the Fura-2 AM 
Ca2+-assay and BrPH and TFMPH in the gene reporter assay, which were analyzed in two independent experiments performed in triplicate; n.d., not 
determined; n.a., not applicable. 
 
c  Determined on membranes of hH1R expressing Sf9 cells. For hH1R binding data determined on membranes of Sf9 cells cf. [40,57]. 
 
4 Label-free versus conventional cellular assays: Functional investigations on the human histamine H1 receptor 
65 
 
4.3.2 Cellular response to H1R agonists in various assays 
To investigate, whether activation of the H1R by ligands other than histamine provides 
different assay-related pEC50 values as well, we selected the agonists shown in Fig. 1 for 
functional studies. All agonists included in this study preferentially induced the recruitment of 
β-arrestin2 over the β-arrestin1 isoform as generally observed for class A GPCRs [59]. 
Unfortunately, it turned out that not all of these compounds are compatible with the different 
assay conditions. In particular, the histaprodifen analogues [57], designated UR-BS 
compounds in the present study, caused cytotoxic effects at concentrations >1 µM (for 
cytotoxicity of selected compounds cf. Figure S3, Supporting Information), most probably due 
their amphiphilic nature. Although the β-arrestin recruitment assays revealed partial agonism 
in the expected concentration range (cf. Table S1, Supporting Information), attempts to 
characterize such compounds in ECIS  and in the Fura-2 calcium assay using U373 MG cells 
[20] as well as in the luciferase gene reporter assays failed (data not shown). In contrast to the 
UR-BS compounds, the phenylhistamine derivative UR-KUM530 [40] proved to be non-toxic 
up to a concentration of 100 µM (cf. Figure S3A, Supporting Information), allowing for the 
determination of pEC50 values in both, the label-free and the conventional assays. As becomes 
obvious from Fig. 3 and Table 1, UR-KUM530 is more potent than histamine in all assays and 
seems to be a superagonist in both, the impedimetric and the DMR assay. Interestingly, the 
concentration-response curve from ECIS is exceptionally steep, resulting in about 30-fold 
higher potency than in the Fura2 assay. The time course of the impedimetric signal was similar 
to that of histamine with regard to the initial dip and the subsequent rise, suggesting Gq 
coupling (data not shown) for this compound, too. By contrast, the investigation of betahistine 
revealed completely different concentration-response curves (Fig. 3): full agonism in the 
aequorin calcium and the luciferase gene reporter assay (Emax: 0.96), but only partial agonism 
in β-arrestin2 recruitment (Emax: 0.80), DMR (Emax: 0.71) and, in particular, in the impedimetric 
assay (Emax: 0.25). The extremely low intrinsic activity observed in the ECIS assay cannot be 
explained. Regardless of the weak increase in ∆|Z|, a transient dip of the signal was observed 
(data not shown). The agonist potency of betahistine was lowest in the DMR and highest in 
the arrestin recruitment assay.  
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Fig. 3: Assay-dependent concentration-response curves of histamine, UR-KUM530 and betahistine (A). 
Radar plots representing pEC50 values (B) and efficacies (C). Experiments were performed using 
HEK293T cells expressing the hH1R and additional constructs: gene rep (luciferase gene reporter assay): 
HEK293T-CRE-Luc-hH1R cells; βaƌƌϮ: ;β-arrestin2 recruitment assay): HEK293T-ARRB2-H1R cells; 
Ca2+(aeq) (aequorin calcium assays): HEK293T-CRE-Luc-hH1R-mtAEQ cells; DMR and ECIS: HEK293T-
CRE-Luc-hH1R-hMSR1 cells. Data were normalized to a solvent control and the maximal response to 
the endogenous ligand histamine in the respective assay. Data represent mean ± SEM from at least 
three independent experiments performed in triplicate. 
 
Potencies and intrinsic activities can increase as a function of receptor density [60]. In cells of 
one and the same genetic background (HEK293T-CRE-Luc-hH1R for calcium, luciferase gene 
reporter, DMR and impedance-based functional assays) our data illustrate that the measured 
potencies and maximal responses vary depending on both, the readout and the chemical 
structure of the agonist. This becomes obvious from concentration-response curves and, in 
particular, from the radar plot in Fig. 3. The potencies of histamine and UR-KUM530 in the 
luciferase gene reporter assay were similar to those obtained in assays exploiting the GTPase 
activity as a proximal readout (Table 1). The efficacy of UR-KUM530 was the same as that of 
histamine except for both label-free assays, which gave a slightly higher maximal response 
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(Fig. 3). This might be interpreted as “superagonism” [61] related to different binding modes 
of histamine and UR-KUM530 [40], resulting in a differential activation of signaling pathways. 
The response to UR-KUM530 was completely inhibited by diphenhydramine (100 µM) or 
mepyramine (10 µM) in both assays, DMR and ECIS, confirming that the effects were H1R 
mediated (data not shown). The pKb values determined from the corresponding inhibition 
curves were 7.68 ± 0.24 and 8.48 ± 0.44 in ECIS and 7.07 ± 0.11 and 8.64 ± 0.32 in DMR for 
diphenhydramine and mepyramine, respectively, which is comparable to the respective 
values determined versus histamine as agonist (Table 1).  
The assay-dependent differences regarding pEC50 and Emax values observed for all agonists 
under study are difficult to explain, as not all assays can be performed under identical 
conditions. However, the order of potency of agonists was consistent between the 
noninvasive and the canonical assays.  
 
4.3.3 Investigation of G protein coupling 
To investigate the contribution of Gi/o and Gq/11 proteins we constructed concentration-
response curves of histamine and UR-KUM530 in the presence of  pertussis toxin (PTX) [31] or 
the cyclic depsipeptide FR900359 (UBO-QIC) [62,63], respectively. 
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Fig. 4: Effect of the Gq-inhibitor FR900359 on the histamine-induced response in DMR, ECIS, gene 
reporter and Ca2+ (aequorin) assays. Experiments were performed using HEK293T cells expressing 
hH1R and additional constructs: DMR and ECIS: HEK293T-CRE-Luc-hH1R-hMSR1 cells; luciferase gene 
reporter: HEK293T-CRE-Luc-hH1R cells; aequorin calcium assay: HEK293T-CRE-Luc-hH1R-mtAEQ cells. 
Data were normalized to a solvent control and the maximal activation of each system by the 
endogenous ligand histamine, respectively. Data represent mean ± SEM from at least two 
independent experiments performed in triplicate. 
 
As becomes obvious from Fig. 4, the histamine response was reduced to a different extent by 
the Gq/11 inhibitor FR900359 depending on the assay. The impedance-based readout as well 
as the aequorin calcium assay revealed a complete lack of response to histamine in the 
presence of at FR900359 at concentrations of 0.1 and 1 µM, respectively. By contrast, the 
DMR signal was reduced by approximately 80% and the luciferase activity (gene reporter 
assay) was lowered by about 50% in the presence of FR900359 at a concentration of 1 µM, 
and the maximal responses could not be further suppressed by FR900359 at a concentration 
of 10 µM (not shown for gene reporter assay). Whereas the blockade of the calcium signal 
was expected due to Gq/11 inhibition, the differential effects of FR900359 on the two holistic 
assays (impedimetry vs. DMR) and on the luciferase activity suggested additional signaling 
pathways to contribute to the respective readouts (DMR and gene reporter assay) upon H1R 
stimulation.  
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In the presence of pertussis toxin at concentrations from 1 to 100 ng/mL, the impedance of 
the histamine-stimulated cells signal remained almost unaffected (Fig. 5), i. e., there is no 
indication of a contribution of Gi to the impedimetric response. This observation is in 
agreement with the complete blockade by the Gq inhibitor FR900359. On the contrary, PTX 
decreased the response in DMR in a concentration-dependent manner resulting in complete 
blockade at a concentration of 100 ng/mL (Fig. 5). Although the DMR response was also 
strongly suppressed by FR900359, the results demonstrate that Gi is involved, too. This 
phenomenon is reminiscent of promiscuous GPCRs, capable of coupling to Gq and Gi, as 
reported for the free fatty acid receptor FFA1 [63], and depending on the cell type, the H1R 
was described to couple to Gq and/or Gi [31,34,64]. This is supported by the effect of PTX and 
the histamine-induced luciferase activity in the gene reporter assay (Fig. 5). Inhibition of Gi by 
PTX (500 ng/mL) resulted in an increase in bioluminescence by approximately 20%. The 
HEK293T-CRE-Luc-hH1R cells were engineered to detect the cyclic AMP dependent expression 
of luciferase. However, in case of H1R stimulation the cAMP cascade is not required, as the 
increase in luciferase activity is elicited by Gq-coupling resulting in an increase in intracellular 
[Ca2+] and subsequent calmodulin dependent phosphorylation of the CRE binding protein 
(CREB) [65-67]. The increase in bioluminescence in the presence of PTX confirms the 
contribution of Gi as an inhibitory component in this assay.  
Generally, the Gβγ diŵeƌ is also capable of interacting with effector proteins. For instance, 
Gβγ ĐaŶ iŶteƌfeƌe ǁith the cAMP pathway [68-70] and can trigger an intracellular increase in 
intracellular Ca2+ by interacting with phospholipase C and Ca2+ channels [71]. Very recently, 
regardless of its selectivity for Gαq over Gαi and Gαs [63], FR900359 was reported to inhibit 
Gβγ-mediated signaling, too [72]. In this context, we investigated the influence of gallein, 
which is supposed to be a reversible inhibitor of Gβγ ǁith a Kd value of 422 nM [73,74]. In the 
presence of gallein at a concentration of 20 µM, the concentration-response curve of 
histamine in the luciferase gene reporter assay on HEK293T-CRE-Luc-hH1R cells remained 
unaffected (data not shown), suggesting that the Gβγ diŵeƌ is Ŷot iŶǀolǀed. 
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Fig. 5: EffeĐt of the Gαi-inhibitor pertussis toxin on the histamine-induced responses in DMR, 
impedimetric (ECIS) and gene reporter assays. Experiments were performed using HEK293T cells 
expressing hH1R and additional constructs: DMR and ECIS: HEK293T-CRE-Luc-hH1R-hMSR1 cells; 
luciferase gene reporter: HEK293T-CRE-Luc-hH1R cells. Data were normalized to a solvent control 
and the maximal activation of each system by the endogenous ligand histamine, respectively. Data 
represent mean ± SEM from at least three independent experiments performed in triplicate. 
 
With respect to the two label-free approaches, it is noteworthy that ECIS reads primarily Gq-
mediated cell shape changes upon histamine stimulation, as FR900359 completely inhibits the 
cellular response. Consistent with the inhibition of the calcium signal in the aequorin assay, 
experiments with a calcium ionophore using U-373 MG cells, constitutively expressing the H1R 
revealed that an increase in intracellular Ca2+ alone was sufficient to produce very similar ECIS 
traces to those upon histamine stimulation (data not shown). The dependence of the ECIS 
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signal on the increase in [Ca2+]i is plausible due to (i) the predominant influence of the actin 
cortex on membrane topography/cell shape and (ii) the fact that [Ca2+]i is a well-known 
modulator of cortical actin (in concert with myosin). Other signaling pathways that are 
potentially triggered by histamine are not mirrored in the signal, when they are not linked to 
cortical actin or reorientation of the membrane. 
In DMR assays, the Gq inhibitor FR900359 could not entirely block the agonist induced 
response, whereas the Gi inhibitor PTX almost entirely reduced the signal. Thus, DMR records 
a response integrating both Gq and Gi-mediated signaling. 
As demonstrated for DMR in Fig. 6, the inhibition of the cellular signal by FR900359 and PTX 
upon stimulation with UR-KUM530 was qualitatively the same as in case of histamine (cf. Fig. 
4 and Fig. 5). There is no indication of a differential activation of signaling pathways, when 
comparing both H1R agonists.  
 
Fig. 6: Effect of the Gq inhibitor FR900359 on the response to the H1R agonist UR-KUM530 in the 
DMR assay. Data were determined on HEK293T-CRE-Luc-hH1R-hMSR1 cells and represent mean ± 
SEM from at least three independent experiments performed in triplicate. 
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4.3.4 Functional characterization of H1 receptor antagonists 
For most of the hH1R antagonists under study, the pKB values were in the same range as the 
functional data (GTPase assay, Sf9 cell membranes) from the literature [58,75] and the binding 
data from our laboratory (Table 2). However, there were some discrepancies, as becomes 
obvious from the inhibition curves and the radar plot in Fig. 7, in particular, in case of 
fexofenadine, when studied in the aequorin assay, and for diphenhydramine, cyproheptadine 
and maprotiline in the impedimetric assay. The data gained from the impedimetric assay 
suggested 10- to 30-fold higher apparent affinity compared to the values determined by 
radioligand competition binding. Except for impedimetric readouts, experiments in the 
antagonist mode do not display a similarly strong assay-dependence for a given antagonist as 
observed in case of agonists (cf. radar plot in Fig. 7). However, there is a trend towards higher 
pKb values in ECIS.  
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Table 2: pKb-values for hH1R antagonists determined in different functional assays and pKi-values determined in radioligand competition binding studies.  
 gene reporter 
(luciferase) 
β-arrestin2 
recruitmenta 
Ca2+ 
(Fura-2 AM) 
Ca2+ 
(aequorin) 
DMRb impedimetryc GTPased competition 
binding 
diphenhydramine 7.66 ± 0.24 7.96 ± 0.04 7.43 ± 0.08 7.62 ± 0.05 7.55 ± 0.05 7.59 ± 0.10 7.81 [58] 7.40 ± 0.03 
mepyramine 8.13 ± 0.10 8.08 ± 0.09 8.85 ± 0.01 8.39 ± 0.12 8.43 ± 0.11 8.70 ± 0.14 8.25 [58] 8.39 ± 0.04 
cyproheptadine 8.55 ± 0.11 8.60 ± 0.06 8.60 ± 0.03 7.99 ± 0.13 8.01 ± 0.14 10.15 ± 0.28 8.72 [58] 8.63 ± 0.05 
maprotiline 8.47 ± 0.12 8.38 ± 0.03 8.58 ± 0.08 8.00 ± 0.05 8.19 ± 0.13 8.84 ± 0.53 8.54 [75] 8.50 ± 0.05  
fexofenadine 7.47 ± 0.03 6.95 ± 0.03 6.85 ± 0.09 6.29 ± 0.03 7.01 ± 0.03 8.23 ± 0.30 6.65 [58] 6.70 ± 0.06 
Functional studies were performed using genetically engineered HEK293T cells (cf. Table 1, footnote) and binding data were determined on HEK293T-CRE-Luc-
hH1R cells. Data represent mean ± SEM from at least three independent experiments performed in triplicate. Functional and binding data of additional H1R 
antagonists investigated in the respective assay, pKb values: a levocetirizine, 7.16 ± 0.07; mirtazapine, 8.71 ± 0.07, clozapine, 7.64 ± 0.05. b mirtazapine, 8.46 ± 
0.10; doxepine, 9.35 ± 0.19; clozapine, 8.21 ± 0.22. c levocetirizine, 8.72 ± 0.14; doxepine, 9.11 ± 0.28; clozapine, 9.60 ± 0.08. d mirtazapine 8.59 [75]; doxepine, 
8.90 [75]; clozapine, 8.36 [75]. 
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Fig. 7: Histamine H1R antagonism of diphenhydramine, mepyramine, cyproheptadine, maprotiline 
and fexofenadine in five different assays. Inhibition curves and radar plot. Experiments were 
performed using genetically engineered HEK293T cells expressing the hH1R and additional constructs; 
gene rep (luciferase gene reporter assay): HEK293T-CRE-Luc-hH1R cells; βaƌƌϮ: ;β-arrestin2 
recruitment assay): HEK293T-ARRB2-H1R cells; Ca2+(aeq) (aequorin calcium assay): HEK293T-CRE-Luc-
hH1R-mtAEQ cells; DMR and imped (impedimetry): HEK293T-CRE-Luc-hH1R-hMSR1 cells. Histamine 
was used at a concentration producing approximately 80% of the maximal response in the respective 
assay. Data were normalized to a solvent control and the EC80-activation of histamine in each system. 
Data represent mean ± SEM from at least three independent experiments performed in triplicate.  
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4.4 Conclusion 
Label-free methods (DMR and impedimetry) and various signaling pathway specific readouts 
were used for the characterization of H1R agonists and antagonists on genetically engineered 
HEK293T cells, i. e., cells of an identical genetic background. For antagonists, the results from 
DMR were compatible with those from conventional readouts, whereas the impedance-based 
data were inconsistent in some cases. Most pronounced differences became obvious for 
agonists regarding both, potencies and efficacies, depending on the chemical structure of the 
ligand and the type of readout, reflecting the complexity of the assays performed in the 
agonist mode. These differences can be explained only in part. The DMR appears to integrate 
both, Gq and Gi mediated signaling (Fig.4 and Fig. 5), the main two pathways described for the 
H1R, as does the gene reporter assay. By contrast, ECIS and calcium assays apparently only to 
reflect Gq signaling. DMR, impedimetry and the Fura-2 assays allow the investigation of cellular 
effects in real time, whereas gene reporter, aequorin, β-arrestin recruitment, GTPase and 
GTPγS assays are endpoint measurements. Distinct histamine H1R ligands did not effect the 
different functional readouts in a uniform way, a phenomenon, which may indicate 
“functional selectivity” or “biased signaling”, provided that off-targets are not involved. As the 
latter cannot be excluded, in addition to different readouts, selective receptor agonists and 
antagonists as well as specific inhibitors of signaling pathways are required as pharmacological 
tools to reduce the risk of misinterpretation and pitfalls. In so far, label-free holistic methods 
such as DMR and impedimetry are reminiscent of investigations on isolated organs and may 
be considered as “integrative pharmacology” at the cellular level. The question arises whether 
human cells constitutively expressing the receptor of interest and originating from the organ 
to be targetted should serve as more appropriate models than genetically engineered cells.  
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4.5.1 H1R-ELucC/ELucN-ARRB expression in HEK293T cells 
The HEK293 cells were seeded in 75 cm2 tissue culture flasks and cultivated for 2 to 3 days in 
DMEM + 10% FCS to a confluency of about 60-90 %. The cells were then washed 3 times with 
ice cold PBS and subsequently lysed with 1 mL of RIPA buffer (20 mM Tris/HCl pH 7.8, 200 mM 
NaCl, 1 mM EGTA, 1 mM, 1% w/v Triton X-100, 5 mM K2HPO4, 1 x protease inhibitor mix 
(Sigma, Steinheim, Germany)). The crude mixture was transferred to 1.5 ml reaction vessels 
and incubated on ice for 20 min. During this period, the vessels were vigorously vortexed 
several times. The cell debris was removed by centrifugation (13000 x g, 5 min). The 
supernatant was mixed with 10% (v/v) glycerol, and aliquots were frozen and stored at -80 °C. 
The protein content of the samples was determined using the DC protein assay kit (Bio-Rad 
Laboratories, Munich, Germany) according to manufacturer’s instructions.  
The protein samples were analyzed by SDS-PAGE on a 12% acrylamide gel according to the 
general procedure established by Laemmli et al. [76]. For gel electrophoresis, 20 µg of protein 
per sample were loaded onto each lane. The samples for the detection of the V5-tagged 
receptor fusion constructs were mixed with 1 volume of 2x sample buffer containing 8 M urea 
and incubated for 30 min at room temperature. The samples for the detection of the c-myc-
tagged arrestin fusion constructs were mixed with 1 volume of 2x sample buffer (Sigma, 
Steinheim, Germany) and incubated for 10 min at 98 °C. The precision plus dual color and 
biotinylated protein ladder (Bio-Rad Laboratories, Munich, Germany) were used as molecular 
weight markers. Electrophoresis was performed at 150 V for approx. 2 h. 
For western blotting, the gels were placed on top of a nitrocellulose membrane between filter 
papers soaked in blotting buffer (25 mM Tris/HCl pH 8.3, 0.2 M glycine, 20% (v/v) methanol). 
Blotting was performed for 45 min at 250 mA. Afterwards, the membranes were incubated 
for at least 1 h in blocking solution (20 mM Tris/HCl pH 7.6, 0.14 M NaCl, 0.1% (v/v) Tween 20, 
5% (w/v) fat free milk powder). After blocking, the membranes were cut closely above the 50 
kDa band of the prestained protein marker. The lower part of the blots were developed using 
the anti β-actin antibody, the upper part using the Pierce anti c-myc antibody (Thermo Fisher, 
Darmstadt, Germany) for detecting the arrestin constructs or the anti V5 antibody (Thermo 
Fisher, Darmstadt, Germany) for the receptor constructs, respectively. Incubations with the 
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primary antibodies were performed using a 1:1000 dilution of the respective AB in blocking 
solution at 4 °C overnight. After 3 washing steps in TBST (20 mM Tris/HCl pH 7.6, 0.14 M NaCl, 
0.1% (v/v) Tween 20) for 10 min each, the membranes were incubated with the secondary 
HRP-coupled antibodies, at a 1:1000 dilution in blocking solution for 1 h at RT. After 3 
additional washing steps, the immunoreactive bands were detected using ECL western 
blotting substrate (Thermo Fisher, Darmstadt, Germany) and the ChemiDoc MP imaging 
system (Bio-Rad Laboratories, Munich, Germany). The scans of the blots were analyzed using 
the Image Lab 5.0 software (Bio-Rad Laboratories, Munich, Germany). 
 
Fig S1: Schematic illustration of the fusion constructs used for the β-arrestin recruitment assay and the 
verification of their expression in HEK293T cells via western blot. A: The split-luciferase-ďased β-
arrestin recruitment assay consists of two fusion proteins containing luciferase fragments of a green 
light-emitting luciferase from the click-beetle Pyrophorus plagiophthalamus (ELuc). The H1R was fused 
C-terminally to the C-teƌŵiŶal fƌagŵeŶt of ELuĐ ;ELuĐCͿ aŶd eitheƌ oŶe of the tǁo β-arrestins (ARRB) 
was fused N-terminally to the N-terminal fragment of ELuc (ELucN). The receptor construct possesses 
C-terminally a V5-tag, ǁheƌeas the β-arrestin constructs feature myc-tags. B: α-V5 antibody detection 
of H1R fusion proteins in lysate of HEK293T cells transfected with H1R-ELucC and either ELucN-ARRB1 
or ELucN-ARRB2. C: α-ŵǇĐ aŶtiďodǇ deteĐtioŶ of β-arrestin fusion proteins in same HEK293T lysate as 
in B. 
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4.5.2 Radioligand saturation binding on HEK293T cells, expressing 
the H1R-ELucC and ELucN-ARRB constructs  
The radioligand saturation binding assays to determine the receptor expression was 
performed using whole cells. The HEK293T cells, expressing the hH1R-ELucC and ELucN-ARRB 
constructs, were cultivated in DMEM +10% FCS in a 75 cm2 cell culture flask to a confluence 
of about 70 – 90%. The cells were detached by treatment with 0.05% trypsin, 0.02% EDTA in 
PBS. After addition of 1/10 volume FCS, cells were harvested by centrifugation (400 x g, 5 min), 
subsequently resuspended in Leibovitz L-15 medium + 1% FCS and adjusted to a cell density 
of 2 million cells/mL. The binding assay was performed in flat bottom, polypropylene 96-well 
microtiter plates. The reaction mixture contained 10 µL of up to 80 nM mepyramine, 55 µl of 
Leibovitz + 1% FCS and 25 µL of cell suspension, giving a concentration of 50000 cells/well. In 
order to save radioligand, 1 part of mepyramine was diluted with 1 part of unlabeled 
mepyramine. The wells for the determination of the total binding contained additional 10 µL 
of Leibovitz, while, for the unspecific binding, 10 µL diphenhydramine at a concentration of 
10 µM dissolved in Leibovitz were added. The mixture was incubated for 60 to 90 min at RT 
under shaking at 300 rpm. Afterwards, the cells were harvested by filtration through GF/C 
filters using a Brandel 96 sample harvester (Brandel, Gaithersburg, MD). After 3 washing steps 
with ice cold PBS, the filter bound radioactivity was measured by liquid scintillation counting 
using the Micro Beta2 1450 scintillation counter (Perkin Elmer, Rodgau, Germany). 
Data analysis was performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, 
CA). Specific binding values were calculated by subtraction of the unspecific binding from the 
respective total binding values. Data was plotted against the corresponding radioligand 
concentration and fitted by nonlinear regression using the one site saturation binding model. 
From the extrapolated Bmax values, the binding sites per cell were calculated using the specific 
activity of the radioligand. 
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Fig S2: Radioligand saturation binding conducted with [3H]-mepyramine on HEK293T cells expressing 
H1R-ELucC and either ELucN-ARRB1 (A) or ELucN-ARRB2 (B). Non-specific binding was determined in 
the presence of 10 µM diphenhydramine and was subtracted from total binding. Resulting specific 
binding was best fitted to a one-site saturation binding equation. KD-values are as follows: 4.5 nM (H1R-
ELucC + ELucN-ARRB1) and 4.4 nM (H1R-ELucC + ELucN-ARRB2) and are in good agreement with 
reference data [57]. Both cell lines show comparable receptor amounts per cell with 5.5 * 105 
ƌeĐeptoƌs/Đell foƌ the β-arrestin1 cell line and 4.7 * 105 ƌeĐeptoƌs/Đell foƌ the β-arrestin2 cell line. 
Data ± SEM from one experiment performed in triplicate.  
 
4.5.3 Cytotoxicity of selected H1R agonists in the crystal violet 
chemosensitivity assay 
The assay was performed as previously described [77]. Accordingly, HEK293T-CRE-Luc-hH1R 
cells in DMEM were seeded into 96 well plates (Greiner, Frickenhausen, Germany) at a density 
of 15 cells per microscopic field (magnification: 320-fold). The cells were allowed to attach 
overnight, and the test compounds were added at the desired concentrations. As a control, 
cells were treated with medium containing only the respective solvent. After various 
incubation periods the cells were fixed with 1 % glutardialdehyde solution and stored at 4 °C. 
At the end of the assay, cells were stained with crystal violet. Prior to measurement, excess 
dye was removed by washing the cells with water, and cell-bound dye was extracted with 70 
% EtOH. Absorbance was measured at 580 nm using a GENios Pro microplate reader (Tecan, 
Salzburg, Austria). Drug effects were expressed as corrected T/C- values, according to 
following equation: ��  ����. (%) =  � − ��� − ��  × 100 
 
where T = mean absorbance of treated cells, C = mean absorbance of controls and C0 = mean 
absorbance of the cells when the test compounds were added (t = 0). 
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When the absorbance was less than that at t = 0, the cytocidal effect was calculated according 
to following equation: 
��������� ������ (%) = �� − ��� × 100 
 
 
Fig. S3: Cytotoxicity assays performed on HEK293T-CRE-Luc-hH1R cells for the compounds UR-KUM530 
(A), UR-BS280 (B) and UR-BS365 (C). Cytotoxicity of each compound was analysed over a time-period 
of at least four days. (Data ± SEM from 16 experiments). 
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4.5.4 H1R agonism of histaprodifen-derived hH1R ligands in the β-
arrestin recruitment assay 
Table S1: pEC50- and Emax values for histaprodifen-derived hH1R ligands in the β-arrestin recruitment 
assay (HEK293T-ARRB1-H1R and HEK293T-ARRB2-H1R cells) and reference data from [32P]GTPase assay 
using membranes of hH1R expressing Sf9 cells.a,b 
 
 β-arrestin1 recruitment β-arrestin2 recruitment GTPase (ref. [57]) 
 pEC50 Emax pEC50 Emax pEC50 or (pKB) Emax 
UR-BS280 5.77 ± 0.06 0.50 ± 0.02 6.01 ± 0.11 0.58 ± 0.10 6.67  0.52  
UR-BS354 n.a. 0.03 ± 0.00 4.99 ± 0.19 0.22 ± 0.04 (6.00)  - 
UR-BS355 5.85 ± 0.07 0.26 ± 0.02 6.16 ± 0.14 0.48 ± 0.05 6.65  0.47 
UR-BS358 5.30 ± 0.25 0.09 ± 0.02 5.48 ± 0.08 0.43 ± 0.03 (6.56)  - 
UR-BS364 n.a. 0.04 ± 0.01 5.49 ± 0.13 0.37 ± 0.08 (6.61)  - 
UR-BS365 6.19 ± 0.10 0.33 ± 0.01 6.56 ± 0.18 0.54 ± 0.05 6.18  0.65 
a Data represent mean values ± SEM of three independent experiments performed in triplicate. n. a. = 
not applicable due to lack of intrinsic activity. 
b For hH1R binding data determined on membranes of Sf9 cells cf. [57] 
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5 Functional investigations of human NPY Y2 and Y4 
receptors: Comparison of label-free and calcium-
based methods 
5.1 Introduction 
The neuropeptide Y family comprises neuropeptide Y (NPY), peptide YY (PYY) and pancreatic 
polypeptide (PP) [1-3]. The peptides are composed of 36 amino acids and are structurally 
closely related [4,5]. In humans, NPY, PYY and PP differentially prefer four functional subtypes 
of the NPY receptor family, GPCRs referred to as Y1R, Y2R, Y4R and Y5R [3]. This multireceptor 
system influences several important physiological key functions and is associated with 
multiple diseases like epilepsy or depression [6-8]. A fifth receptor (y6) was cloned from mouse 
genomic DNA [9], but up to now, no physiological correlate of the cloned y6 receptor has been 
described [3,10]. After agonist-induced NPY receptor activation, the receptor is coupling to G-
proteins of the pertussis toǆiŶ seŶsitiǀe Gαi/o family [3,11]. Receptor activation results in the 
inhibition of adenylyl cyclases and, therefore, in a decrease in cyclic adenosine 
monophosphate (cAMP) formation [3]. Depending on the cell type, additional signaling 
pathways are reported, including the modulation of calcium and potassium channels 
[3,12,13]. The inhibition of the cAMP response has been a standard assay for the functional 
characterization of ligands on all NPY receptor subtypes [14-18]. Another method for the 
functional investigation of NPY Y2 and Y4 receptor ligands is based on the use the chimeric G-
protein Gqi5, redirecting the cellular response to a calcium signal, which can be measured with 
classical fluorescence dyes (e. g. fura-2) or by bioluminescence as, for example, described for 
mitochondrially targeted apoaequorin [19,20].  
This chapter is dealing with the exploration of two label-free assays (ECIS and DMR) with 
respect to the functional characterization of the NPY Y2 and Y4 receptor, respectively. For this 
purpose, selected receptor ligands were analysed and the data were compared with those 
from conventional calcium assays. Furthermore, the influence of the Gαi inhibitor pertussis 
toxin and the Gαq inhibitor FR900359 (UBI-QIC) on the response in the label-free and the 
calcium assay was investigated.     
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5.2 Materials and Methods 
All chemicals were from commercial suppliers, unless otherwise indicated, as specified in 
chapters 3 and 4.   
 
5.2.1 Human neuropeptide Y2 and Y4 receptor ligands 
The porcine NPY and [K4]hPP was kindly provided by Prof. Dr. Chiara Cabrele (University of 
Salzburg). Stock solutions (1 mM) were prepared in 10 mM HCl and stored at -20 °C. 
Compounds 1-4 [21] and (UR-MEK388 [22] (5 mM stock solution in 100 % DMSO) as well as 
BIIE 0246 (10 mM stock solution in 10 % DMSO) [23] were synthesized in our lab [23]. For 
label-free measurements,  stock solutions were thawed and diluted with Leibovitz’ L-15 
medium supplemented with 1 % bovine serum albumin (BSA, Serva Electrophoresis, 
Heidelberg, Germany) and 0.1 mg/mL Bacitracin (Sigma-Aldrich, Taufkirchen, Germany). Y4 
receptor ligands were diluted in “siliconized” Eppendorf reaction vessels to prevent 
adsorption. For fura-2 and aequorin calcium assay, stock solutions aliquots were diluted in 
loading buffer (pH 7.4; 25 mM HEPES, 120 mM NaCl, 1.5 mM CaCl2, MgCl2, 5 mM KCl, 10 mM 
D-glucose) supplemented with 1 % BSA and 0.1 mg/mL bacitracin as previously described [20].    
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Fig. 5.1: Chemical structures of selected hY2 and hY4 receptor agonists and antagonists.  
 
5.2.2 Cell culture 
CHO-K1 [19], CHO-hY2-mtAEQ [19], CHO-hY2-Gqi5-mtAEQ [19]  and CHO-hY4-Gqi5-mtAEQ [20] 
cells were cultured as described elsewhere.  
 
5.2.3 Aequorin calcium assay 
The assay was performed as described previously [19,20]. 
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5.2.4 Fura-2 calcium assay  
The fura-2 calcium assay was performed as described in chapter 4. 
 
5.2.5 Impedimetric assay  
For the investigation of hY2R agonists, PTX and FR900359 (UBO-QIC) on CHO cells, the assay 
was performed as described in chapters 3 and 4. The frequency scans were performed with 
an ECIS-)θ deǀiĐe foƌ 8-well electrode arrays (type 8W10E+) from Applied BioPhysics (Troy, 
NY, USA). A volume of 400 µL of cell suspension, prepared in HAM’s F12 nutrient mixture 
(Sigma Aldrich) containing 10% FCS from an almost confluent cell layer trypsinized from a cell 
culture flask, was dispensed at a density of 1.2∙105 cells per well.  Approximately 60 min before 
the assay the culture medium was replaced by 200 µL of serum-free L-15 medium 
supplemented with 1% BSA and 0.1 mg/mL bacitracin. The impedance-based experiments 
were performed with an ECIS-Z device for 96-well electrode arrays (type 96W1E+) from 
Applied BioPhysics. A volume of 300 µL of cell suspension, prepared in HAM’s F12 nutrient 
mixture containing 10% FCS was dispensed at a density of 4.5∙104 cells per well. About 60 min 
before the assay the culture medium was replaced by 150 µL of serum-free L-15 medium 
supplemented with 1% BSA and 0.1 mg/mL bacitracin. Data were recorded with the ECIS 
device placed in an incubator (Galaxy 48S, New Brunswick, USA), containing a humidified 
atmosphere at 37 °C at an AC frequency of 10 kHz. For data processing cf. [24]. Antagonists 
and the agonist were applied simultaneously. 
 
5.2.6 Dynamic mass redistribution assay 
The assay was performed as described in chapters 3 and 4, using CHO cells expressing the 
receptor of interest. A volume of 40 µL of cell suspension, prepared by trypsinization from 80 
% confluent cell layers, in HAM’s F12 nutrient mixture supplemented with 10% FCS was 
dispensed at a density of 2∙104 cells per well into uncoated 384-well EnSpire microplates. The 
cells were washed four times with serum-free L-15 medium supplemented with 1% BSA and 
0.1 mg/mL bacitracin and allowed to equilibrate in a volume of 30 µL of the same medium per 
well in the multimode reader at 37 °C for about 60 min. For data processing cf. [24]. 
Antagonists and the agonist were applied simultaneously. 
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5.3 Results and discussion 
5.3.1 Determination of the optimal cell density for CHO-hY2-Gqi5-
mtAEQ cells in label-free assays  
To characterize the DMR and impedance response of the hY2 receptor, the cell density was 
optimized for both assays  (Fig. 5.2). The addition of 300 nM (DMR) or 10 nM (ECIS) pNPY 
caused a positive mass redistribution and an increase of the recorded impedance. pNPY was 
chosen instead of human NPY, because hNPY contains a methionine residue in position 17 
that is susceptible to oxidation. The maximal cellular response was observed at a density of 
2.0∙104 cells/well for DMR and 4.5∙104 cells/well for impedance experiments. 
 
Fig. 5.2: Dependence of the pNPY induced response on the density of CHO-hY2 cells, recorded by 
DMR (A) and ECIS (B). (A) DMR response caused by 300 nM pNPY at various CHO-Y2 cell densities in 
384-well plates. (B) Cell density dependent signal intensity in the ECIS assay after addition of 10 nM 
pNPY. Cells were plated in a range from 1.5 ∙ 104 to 4.5 ∙ 104 cells per well.  
 
 
 
 
 
 
-10 0 10 20 30 40
0
100
200
300
400
500
0.5 ⋅ 104
1.0 ⋅ 104
1.5 ⋅ 104
2.0 ⋅ 104 cells/well
t / min
∆λ
 
/ p
m
-10 0 10 20 30 40
0
500
1000
1500
2000
1.5 ⋅ 104
2.3 ⋅ 104
4.5 ⋅ 104 cells/well
t / min
∆IZ
I /
Ω
A B
5.3 Results and discussion 
92 
 
5.3.2 Effective range of measurement depending on the frequency of 
the alternating current (AC) 
Frequency scans were performed to compare the impedance measured with cell-free 
electrodes and electrodes covered with monolayers of CHO-hY2-Gqi5-mtAEQ cells. The 
impedance as a function of frequency for an electrode with an area of 0.49 cm2 (8W10E: 8 
wells à 10 electrodes) is shown in Fig. 5.3A. The effective range of measurement was recorded 
between 103 and 105 Hz. The maximum of the normalized impedance as a function of 
frequency becomes obvious from Fig. 5.3B. As the maximum of this curve is supposed to 
reflect  highest sensitivity [25] for this type of cells, ECIS experiments were performed at a 
frequency of 10 kHz. 
Fig. 5.3: (A) Frequency-dependent impedance traces of electrodes covered with a confluent 
monolayer of CHO-hY2 cells in L15 + 1 % BSA + 0.1 mg/mL bacitracin and cell-free electrodes in the 
same culture medium. (B) Normalized impedance corresponding to the ratio of impedance of the 
cell-covered electrode and the impedance of the cell-free electrode measured at the same 
frequency.   
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5.3.3 Functional characterization of hY2 receptor ligands  
 Porcine neuropeptide Y and the selective hY2 receptor antagonist BIIE 0246 were studied in 
with ECIS and DMR using CHO-hY2 cells. The results were compared with those obtained from 
conventional functional assays, namely mobilization of intracellular calcium in the fura-2 and 
in an aequorin-based assay. AĐtiǀatioŶ of the Gαi/o coupled hY2 receptor induced an increase 
in cellular impedance in ECIS (Fig. 5.4A) and a shift towards longer wavelengths in DMR (Fig. 
5.4C). Control experiments performed with CHO cells devoid of hY2 receptors did not respond 
to agonist addition. The shape of the curves (Fig. 5.4) was similar in both label-free assays. 
pNPY induced an immediate sharp rise after compound addition. The signal peaked in a first 
maximum at approximately 5 min. The transient minimum was reached in both assays within 
minute 5 to 10. Subsequently, an increase was observed within 10 to 20 minutes, before the 
signal decayed slowly. The signalling fingerprints of the ŵajoƌ Gα pƌoteiŶ Đlasses ǁeƌe 
reported for both label-free techniques [26-28] (cf. Figure 1.3, chapter 1). According to these 
studies, the oǀeƌall ƌespoŶse ĐaŶ ďe assigŶed to the Gαi protein, regardless of minor 
differences, which may arise from the chimeric G-protein Gqi5. The Gαi 
Fig. 5.4: pNPY-induced response of  CHO-hY2-Gqi5-mtAEQ cells recorded by ECIS (A, B) and DMR (C, 
D). (A) Representative time courses (performed in triplicate) of the concentration-dependent 
change of impedance (recorded at 10 kHz) or resonance wavelength (C). (B,D) Concentration-
response curves derived from areas-under-the curve (AUC) of baseline-corrected data integrated 
from 0 – 40 min for at least four independent experiments, each performed in triplicate. 
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protein mainly contributes to the impedimetric readout, because the characteristic Gαq 
protein associated dip immediately after agonist addition [29] (cf. Fig. 1.3, chapter 1) is 
missing. Moreover, a second maximum, typical for a Gαi mediated signal, was recorded. The 
pEC50 values determined for pNPY depended on the type of label-free and calcium assay (Table 
5.1). ECIS revealed the highest potency of pNPY with an pEC50 of 9.37, whereas the DMR and 
the fura-2 assay gave comparable results (pEC50 values: 8.58 and 8.47), and the aequorin 
calcium assay gave the lowest pEC50 value. Interestingly, the differences between  
 
 
binding (Kd = 0.7 ± 0.2 nM [19]) and functional data was less pronounced in the impedimetric.  
It may be speculated that cellular signalling mechanisms other than the calcium response 
contribute to the holistic readout. Moreover, the pNPY potency obtained in the fura-2 calcium 
assay was higher than the value, generated in the aequorin assay. A similar result was already 
reported before [19], although the discrepancy between the assays was much higher in the 
recent experiments. Apparent discrepancies between the data from the calcium assays could 
result from the different assay procedures. Especially, the shear stress caused by the injection 
of the cell into the pNPY-containing wells in the aequorin assay could be a critical issue.  
To investigate the effect of the chimeric G-protein Gqi5, the CHO-hY2-Gqi5-mtAEQ cells were 
compared with the CHO-hY2-mtAEQ cells in the optical label-free assay (Fig. 5.5). Surprisingly, 
concentration-dependent signals of similar curve shapes were recorded with both cell types. 
The determined potency of pNPY was slightly lower in the cells without chimeric G-protein 
(pEC50: 8.29) compared with the cells expressing the Gqi5 construct (pEC50: 8.58). The efficacy 
of pNPY in the cells without Gqi5 was about 80 % of the maximal agonist signal measured with 
the cells expressing the chimeric G-protein. In contrast to the fact that mobilisation of  
Tab. 5.1: Potencies (pEC50 ± SEM) of pNPY determined in the optical and impedimetric label-free assay 
compared to calcium assays 
Cells DMRa ECISa fura-2a Aequorina 
CHO-hY2-Gqi5-mtAEQ 8.58 ± 0.08 9.37 ± 0.12 8.47 ± 0.09 7.84 ± 0.19 
CHO-hY2-mtAEQ 8.29 ± 0.13 n.d. n.d. n.d. 
aAssays on CHO-hY2-Gqi5-mtAEQ cells. Data were analyzed by nonlinear regression and were best fitted to 
four-parameter sigmoidal concentration-response curves. Data shown are the means ± SEM of at least two 
independent experiments. Investigations in label-free and aequorin assay were performed in triplicate. Fura-2 
calcium assay: one experiment performed in triplicate. 
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intracellular calcium by pNPY in the fura-2 assay was weak in CHO-Y2 cell devoid of the 
chimeric G-protein [19], the DMR assay revealed nearly full intrinsic activity on cells without 
Gqi5. Obviously, the G-proteins endogenously expressed in CHO cells suffice to give apply DMR 
as a functional readout, making genetic engineering with regard to re-direction of the cellular 
signal unnecessary. To explore whether the measured DMR signal is Y2 receptor-mediated, 
the selective high affinity NPY Y2 receptor antagonist BIIE 0246 was investigated in the optical 
label-free assays (Fig. 5.6). It was reported in previous studies that BIIE 0246 behaves as an 
insurmountable antagonist after pre-incubation [19,30]. Therefore, BIIE 0246 at different 
concentrations was co-administered with a constant submaximal agonist (c(pNPY) = 30 nM) 
concentration. The  
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Fig. 5.5: (A, B) pNPY-induced DMR response of  CHO-hY2 cells devoid of  (A, CHO-hY2-mtAEQ cells) or 
expressing the Gαqi5 protein (B, CHO-hY2-Gqi5-mtAEQ cells). Peptide solutions contained 1% BSA to 
reduce adsorption to the surface of plate and 0.1 mg/mL bacitracin in order to prevent protease-
mediated degradation of pNPY. (C) Comparison of the concentration-response curves of pNPY. The 
response was normalized to a solvent control and referred to the maximal effect of pNPY in the 
CHO-hY2-Gqi5-mtAEQ cells, expressing the chimeric G-protein. Data are means ± SEM of at least 3 
independent experiments, each performed in triplicate.  
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determined KB value of BIIE 0246 (KB = 10.47 nM) was in good agreement with previously 
reported data for the fura-2 assay (KB = 28.9 nM) [19]. The antagonist could suppress the pNPY 
induced signal in the impedimetric assay as well (data not shown). Because of technical 
problems with the ECIS apparatus, the experiment could not be repeated. 
 
5.3.4 Investigation of G-protein coupling of the human NPY Y2 
receptor 
To analyse the contribution of Gαi/o aŶd GαƋ/ϭϭ pƌoteiŶs, ĐoŶĐeŶtƌatioŶ-response curves of 
pNPY were constructed in the presence of pertussis toxin oƌ the GαƋ/ϭϭ iŶhiďitoƌ FR9ϬϬ359 
(UBO-QIC) [31,32], respectively. Pertussis toxin catalyzes the ADP-ribosylation of 
the αi subunit of the heterotrimeric G protein, preventing the interaction with GPCRs, due to 
the Gi subunits remaining locked in the GDP-bound state [33-35] . Pertussis toxin influences 
cellular response by different mechanisms. The inhibition is resulting in an uncoupling of the 
Gαi/o pƌoteiŶ fƌoŵ the ƌeĐeptoƌ aŶd the fiŶal suppƌessioŶ of the iŶtƌaĐellulaƌ sigŶal 
transduction.  The depsipeptide FR900359 is structurally very similar to YM-254890 and shows 
similar pharmacological activity [36]. The reason for the YM-254890 mediated inhibition of 
the GαƋ/ϭϭ sigŶal tƌaŶsduĐtioŶ is the prevention of the GDP-GTP eǆĐhaŶge iŶ GαƋ/ϭϭ [37]. 
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Fig. 5.6: Inhibition of the NPY induced signal by BIIE 0246 on CHO cells stably co-expressing the hY2 
receptor, Gqi5 and mtAEQ in the DMR assay. (A) Inhibition of the pNPY (30 nM) induced response by 
co-applied BIIE 0246. (B)  Concentration-response curve of BIIE 0246 (pKB: 7.98 ± 0.13). Data are 
means ± SEM of 2 independent experiments, each performed in triplicate. 
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As becomes obvious from Fig. 5.7, the pNPY ƌespoŶse ǁas ƌeduĐed ďǇ the Gαq/11 inhibitor 
FR900359 in both, CHO-hY2-Gqi5-mtAEQ and CHO-hY2-mtAEQ cells. In case of the cells 
expressing the chimeric G-protein the concentration-response curve of pNPY was not shifted 
but depressed by approximately 20%  to 30 % in the presence of FR900259 at increasing 
concentrations . The depression of the pNPY signal in the presence of 10 µM FR900259 was 
almost on the same level as the sigŶal suppƌessioŶ Đaused ďǇ ϭ µM Gαq/11 inhibitor. 
Interestingly, 0.1 µM of FR900259 reduced the pNPY signal in cells without chimeric G-protein 
by roughly 20 % as well, and the concentration-response curve was leftward shifted. It seems 
that in DMR the chimeric G-protein is less involved in the neuropeptide Y2 receptor signalling 
than expected. This is in contrast to the fura-2 (data not shown) and aequorin calcium (Fig. 
5.8) assays. Both, the aequorin and the fura-2 assay, revealed a complete lack of response to 
pNPY iŶ iŶ the pƌeseŶĐe of FR9ϬϬ359 at a ĐoŶĐeŶtƌatioŶs ≥Ϭ.ϭ µM. BǇ ĐoŶtƌast, iŶ the pƌeseŶĐe 
of 5 and 50 ng/mL pertussis toxin, only a depression and a slight rightward shift became 
obvious. These results suggest that the pNPY induced DMR signal is in part and the calcium 
sigŶal is ĐoŵpletelǇ ŵediated ďǇ eŶdogeŶouslǇ eǆpƌessed Gαq/11 and/or the chimeric G-
protein, respectively. The capability of the Y2 ƌeĐeptoƌ to Đouple to the Gαq/11 protein was 
described for rabbit smooth muscle cells [38].  
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Fig. 5.7: Effect of the Gαq-inhibitor FR900359 on the pNPY-induced response in the DMR assay. 
Experiments were performed using (A) CHO-hY2-Gqi5-mtAEQ and (B) CHO-hY2-mtAEQ cells. Data 
were normalized to a solvent control and the maximal activation by the agonist pNPY on the cells of 
interest. Data represent means ± SEM of at least 2 independent experiments performed in triplicate. 
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As the inhibition of the hY2 receptor mediated DMR signal by the FR900359 was incomplete 
and the hY2 ƌeĐeptoƌ is kŶoǁŶ to pƌefeƌeŶtiallǇ Đouple to the Gαi/o protein [3], the effect of 
pertussis toxin (PTX) was investigated.  In the presence of pertussis toxin at concentrations 
from 1 to 100 ng/mL, the DMR signal of the pNPY-stimulated cells was reduced in a 
concentration-dependent manner resulting in an almost completely blocked response (Fig. 
5.9).  
 
 
Fig. 5.8: 
Aequorin assay 
with CHO-hY2-
Gqi5-mtAEQ cells. 
Concentration-
response curves 
of pNPY in the 
presence of 
FR900359, PTX 
or without 
inhibitor. (Mean 
values ± SEM, 
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Fig. 5.9: DMR 
response in CHO-hY2-
Gqi5-mtAEQ cells in 
the absence and 
pƌeseŶĐe of the Gαi/o 
inhibitor PTX. Data 
were normalized to a 
solvent control and 
the maximal 
activation by the 
agonist pNPY. Data 
represent means ± 
SEM of at least 2 
independent 
experiments 
performed in 
triplicate. 
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Compared to the DMR method the pNPY induced effect was just partly inhibited in the fura-2 
(data not shown) and aequorin calcium assay (Fig. 5.8). Due to the expression of the chimeric 
G-protein in CHO-hY2-Gqi5-mtAEQ cells an almost complete reduction of the pNPY signal by 
PTX was not expected. These findings suggest not only a specific Gi/o inhibition but also a partly 
blockade of the chimeric G-protein in the presence of PTX. It could be possible that the PTX 
mechanism of action is responsible for these findings. Pertussis toxin ADP-ribosylates the 
aŵiŶo aĐid ĐǇsteiŶe iŶ the ĐaƌďoǆǇl teƌŵiŶus of the α suďuŶit of the Gαi/o protein and inhibits 
the signal transduction [39]. This cysteine residue belongs to those five C-terminal amino acids 
of the Gαi/o protein, which were used to eŶgiŶeeƌ the ĐhiŵeƌiĐ G pƌoteiŶ Gαqi5 by replacing 
the C-terminus iŶ Gαq/11 to improve the coupling efficiency to the hY2 receptor [40]. Whereas 
the DMR response was strongly pertussis toxin sensitive, the results from the calcium assays 
suggested a predominantly  Gαq/11 mediated response.  
 
5.3.5 Functional characterization of hY4 receptor ligands in the DMR 
and aequorin calcium assay 
A selection of structurally different agonists and antagonists (cf. section 5.2.1) were studied 
in the DMR and aequorin calcium assay, respectively. Cells expressing the hY4 receptor were 
seeded to perform the DMR assay by analogy with the experiments described for CHO cells 
expressing the hY2 receptor. The results for hY4 receptor agonists in the DMR assay and the 
aequorin calcium assay are summarized in Table 5.2 and Fig. 5.10.  
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Fig. 5.10: [K4]hPP induced DMR signal on CHO cells expressing the hY4 receptor. (A) Representative 
agonist induced traces. (B) Concentration response curve from the area under the curve (0 – 40 min). 
Data represent means ± SEM of at least 2 independent experiments performed in triplicate. 
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[K4]hPP induced an immediate sharp increase after addition. The signal peaked in a first 
maximum at approximately two minutes. A transient relative minimum was reached after 
approximately five minutes. Subsequently, a second positive wavelength shift was recorded. 
The DMR signal resulted in a constant level from minute 15 on. The shape of the curves 
suggest a Gαi protein mediated response [26,27]. The pEC50 values of the analysed agonists 
were comparable to data from other assays [21]. As reported, the configuration of the stereo 
centers in the 2,7-diaminosuberic acid linker of Y4R agonists derived from the C-terminal 
pentapeptide of hPP has an impact on Y4R potency [21]. In the label-free assay (2R,7R)-3 was 
3.5 times more potent than (2S,7S)-3 (stereochemical discriminators refer to the chiral centers 
in the linker). A similar difference was determined in the calcium assay (pEC50 values: 8.17 
(2R,7R)-3 vs. 7.76 (2S,7S)-3). Similarly, a stereochemical discrimination was determined for the 
propionylated analogues (2R,7R)-4 and (2S,7S)-4. As demonstrated recently [21], the 
replacement of one of the ‘inner arginines’ in 1 by the NG-carbamoylated arginine results in 
an increased Y4R agonist potency. In the DMR assay, 2 was about 25 times more potent than 
1. Both compounds showed the same or slightly lower efficacy than [K4]hPP. Most agonists 
showed a higher potency in the label-free assay compared to the aequorin calcium assay. 
 
Tab. 5.2: NPY Y4R agonist potencies (pEC50) of `dimeric´ pentapeptides and reference compound [K4]hPP. 
 DMRa Aequorin assaya,b 
Compound pEC50 ± SEM Emax pEC50 ± SEM Emax 
[K4]hPP 8.97 ± 0.17  1.00     8.07 ± 0.03[20] 1.00 
1 8.04 ± 0.15 0.99 7.35 ± 0.10[21] 0.75 
2 9.44 ± 0.23 0.85 8.25 ± 0.12[21] 0.80 
(2R,7R)-3 8.29 ± 0.13 n.d. 8.17 ± 0.03[21] 0.80 
(2S,7S)-3 7.75 ± 0.18 n.d. 7.76 ± 0.04[21] n.d. 
(2R,7R)-4 8.12 ± 0.08 n.d. 7.87 ± 0.06[21] n.d. 
(2S,7S)-4 7.67 ± 0.17 n.d. 7.24 ± 0.04[21] n.d. 
aAssays on CHO-hY4-Gqi5-mtAEQ cells. Data were analyzed by nonlinear regression and were best fitted to 
four-parameter sigmoidal concentration-response curves. Emax: maximal response relative to [K4]hPP (Emax = 
1.00). pEC50: -logEC50. Data shown are the means ± SEM of at least two independent experiments. bData were 
taken from Kuhn et al. (2016), ref. [21] 
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The [K4]hPP induced signal was suppressed by the hY4R antagonist UR-MEK388 in the DMR 
(pKB : 6.67 ± 0.12) and in aequorin calcium assay  
 
5.4 Conclusion 
The applicability of label-free techniques (DMR and ECIS) was explored in comparison to two 
calcium assays (fura-2 and aequorin) for the characterization of hY2 and hY4 receptor ligands 
on cells expressing the receptor of interest, the chimeric G-protein Gqi5 and mitochondrially 
targeted aequorin. Moreover, the effect of the Gαq/11 aŶd Gαi/o proteins inhibitors FR900359 
(UBO-QIC) and pertussis toxin (PTX) was investigated.  
hY2 receptor. The stimulation of the hY2 receptor by pNPY resulted in concentration-
dependent signals in ECIS aŶd DMR. The iŶhiďitioŶ of the Gαq/11 protein with FR900359 caused 
a partial reduction of the DMR signal, whereas in the presence of the Gαi/o inhibitor PTX, the 
DMR signal was almost completely inhibited. Similar findings were recorded in cells which do 
not express a chimeric G-protein. Obviously, the endogenously expressed G-proteins are 
sufficient to give a cellular response. In the presence of FR900359, the calcium signal was 
completely suppressed, whereas PTX only slightly reduced the signal. Depending on the assay, 
stimulation of the hY2 receptor preferentially activates different signalling patterns 
characteristic of either the Gαq/11 or the Gαi/o pathway.  
hY4 receptor. The stimulation of the hY4 receptor by [K4]hPP and other agonists caused a 
concentration-dependent effect in the DMR assay. Most of the investigated agonists were 
more potent in the optical label-free assay than in the aequorin calcium assay.  
It may be speculated that, in addition to Ca2+ mobilization, other cellular signalling 
mechanisms contribute to the holistic readout. The ĐoŶtƌiďutioŶ of eitheƌ the Gαq/11 or the 
Gαi/o pathway could not be unambiguously elucidated. The discrepancies between the effects 
of the applied G-protein inhibitors on the different cells in the conventional and label-free 
assays may be attributed to the chimeric G-protein. 
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6 Summary 
Label-free cell-based assays have been attracting growing attention in drug research. In this 
context, optical approaches based on evanescent electric fields (e.g. resonant waveguide 
grating, RWG; dynamic mass redistribution, DMR) and electrochemical impedance analysis (e. 
g. electric cell-substrate impedance sensing, ECIS) are the most widespread techniques. The 
aim of this doctoral thesis was to optimize and to explore the potential of two label-free 
methods, DMR and ECIS, to functionally characterize ligands of prototypical aminergic and 
peptidergic G-protein coupled receptors (GPCRs). For this purpose, histamine H1 and 
neuropeptide Y (NPY) Y2 and Y4 receptors were selected as examples.  
With respect to the optimization of the conditions for the investigation of the human 
histamine H1 receptor (H1R), native U-373 MG glioblastoma and genetically engineered HEK 
293T cells, either expressing the H1R alone or in combination with the adhesion protein hMSR1 
were used. Reduced cell adhesion to the surface of the sensing devices affected both, the 
optical and the impedance-based readout, but became much more obvious in case of the 
DMR-assay. The co-expression of hH1R and hMSR1 in HEK 293T cells strongly enhanced the 
signal compared to hH1R expression alone. As the sensitivity of the optical readout is confined 
to a distance of 100-200 nm from the surface, depending on the wavelength of the incident 
light, this observation is in accordance with tighter adhesion of the co-transfectants, inducing 
a shorter distance between the cell membrane and the substrate. Cell adhesion was found to 
have a critical impact on the results of label-free cell monitoring, in particular when techniques 
based on evanescent electric fields are applied. 
To explore the applicability and the potential of label-free assays, a set of H1R agonists and 
antagonists was characterized by DMR, ECIS and the data were compared with those from 
various signaling pathway specific readouts (Fura-2 and aequorin calcium assays, arrestin 
recruitment (luciferase fragment complementation) assay, luciferase gene reporter assay), 
gained from genetically engineered HEK293T cells. Additionally, reference data from GTPase 
assays and radioligand binding were considered. Histamine and other H1R agonists 
(betahistine, UR-KUM530) gave different assay-related pEC50 values, however, the order of 
potency was retained. In the luciferase fragment complementation assay, the H1R preferred 
β-arrestin2 over β-arrestin1. The calcium and the impedimetric assay depended on Gαq 
coupling of the H1R, as demonstrated by complete inhibition of the histamine-induced signals 
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in the presence of the Gαq inhibitor FR900359 (UBO-QIC). Whereas partial inhibition by 
FR900359 was observed in DMR and the gene reporter assay, pertussis toxin (PTX) 
substantially decreased the response in DMR, but increased the luciferase signal, reflecting 
the contribution of both, Gαq and Gi, to signalling in these assays. For antagonists, the results 
from DMR were essentially compatible with those from conventional readouts, whereas the 
impedance-based data revealed a trend towards higher pKb values. ECIS and calcium assays 
apparently only reflect Gαq signaling, whereas DMR and gene reporter assays appear to 
integrate both, Gαq and Gαi mediated signaling. Regardless of that, the results confirm the 
value of the label-free methods, DMR and ECIS, for the characterization of H1R ligands.  
As a model for peptidergic GPCRs, CHO-Gqi5-mtAEQ cells co-expressing the human NPY Y2 (Y2R) 
or Y4 receptor (Y4R), the chimeric Gα protein Gqi5 and mitochondrially tagged aequorin were 
selected. The applicability of DMR and ECIS was explored in comparison to two calcium assays 
(Fura-2 and aequorin). The stimulation of the Y2R by pNPY resulted in concentration-
dependent signals in ECIS and DMR. The inhiďition of Gαq/11 by FR900359 caused a partial 
reduĐtion of the DMR signal, whereas in the presenĐe of the Gαi/o inhibitor PTX, the DMR 
signal was almost completely inhibited. In CHO cells which do not express a chimeric G-
protein, pNPY gave a strong DMR signal, suggesting that endogenously expressed G-proteins 
are sufficient to give a cellular response. This effect was only slightly reduced by FR900359. In 
both calcium assays with CHO-hY2-Gqi5-mtAEQ cells, PTX only slightly reduced the signal, 
whereas FR900359 completely suppressed the response. Depending on the assay, stimulation 
of the Y2R preferentially resulted in different signalling patterns characteristic of either the 
Gαq/11 or the Gαi/o pathway.  
The stimulation of the hY4 receptor by [K4]hPP and other agonists caused a concentration-
dependent effect in the DMR assay. Most of the investigated agonists were more potent in 
the optical label-free assay than in the aequorin calcium assay. It may be speculated that, in 
addition to Ca2+ mobilization, other cellular signalling mechanisms contribute to the holistic 
readout. The Đontriďution of either the Gαq/11 or the Gαi/o pathway could not be 
unambiguously demonstrated. The discrepancies between the effects of the applied G-protein 
inhibitors on the different cells in the conventional and label-free assays may be attributed to 
the chimeric G-protein.  
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In summary, both noninvasive techniques are complementary to each other, but cannot fully 
replace reductionist signaling pathway focused assays. 
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